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ABSTRACT 
Tubedown (N aa15) is a protein that associates with the acetyltransferase Arrest 
defective protein 1 (Naal 0) and is involved in the regulation of vascular homeostasis of 
the retina. In endothelial cells Tubedown interacts with the actin-binding protein 
Cortactin. Cortactin is a known regulator of the permeability of molecules through cells 
(transcytosis) and between cells (paracytosis). Transcytosis is enhanced by the 
phosphorylation of Cortactin at tyrosine residues. Recent studies have shown that stable 
suppression of Tubedown expression leads to increased endothelial cell permeability. 
Increased permeability leading to pathological angiogenesis is observed within patients 
with wet age-related macular degeneration (AMD), proliferative diabetic retinopathy 
(PDR), and retinopathy of prematurity (ROP). Previous studies have revealed that 
patients with wet AMD, PDR, and ROP, have decreased levels of Tubedown in 
correlation with areas of pathological angiogenesis. The present work aims to investigate 
Tubedown' s mechanistic involvement in retinal permeability pathways, to further 
elucidate its role in ocular neovascular diseases. 
Immunoprecipitation and western blotting techniques were used to explore 
possible interactions between Tubedown and known regulators of permeability pathways: 
Dynamin, Afadin-6 (AF-6), Y421-Phospho-Cortactin, c-Src, and Zona Occludins-1 (ZO-
1 ). These results provided evidence that the mechanism by which permeability is 
regulated by Tubedown does not likely involve an interaction with Dynamin, AF -6, c-
Src, or Z0-1. The specific interaction of Tubedown with non-phosphorylated Cortactin 
but not Y421-Phospho-Cortactin suggests that Tubedown may attenuate phosphorylation 
.. 
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of Cortactin and subsequently decrease transcytosis. Furthermore, in vitro transient and 
stable knockdown techniques for Tubedown expression were combined with 
immunofluorescence microscopy to determine if reduced Tubedown levels affect the 
distribution of the paracytosis regulator Z0-1 in cultured rhesus macaque retinal-
choroidal endothelial cells. While stable Tubedown knockdowns showed decreased 
Z0-1 cell perimeter expression, transient Tubedown knockdowns had no effect on Z0-1 
cell perimeter distribution. Tubedowns effect on Z0-1 perimeter distribution remains 
inconclusive. 
111 
ACKNOWLEDGEMENTS 
I would like to thank my supervisors, Drs. Helene Paradis and Robert Gendron, 
for their guidance, support, and financial assistance throughout the pursuit of my M.Sc. 
program. I would also like to thank Kerri Smith and Dr. Jules Dore for their helpful 
training which enabled me to successfully complete my research. Also, thanks to my 
supervisory committee member, Dr. Ann Dorward, for her invaluable guidance and 
encouragement. 
I would like to thank all lab members, Dr. Ewa Miskiewicz, Jackie Walker, 
Danielle Gardiner, and Krista Squires for their assistance within the lab. Thank you, Nhu 
Ho for all your support throughout my entire M.Sc. program. 
Thank you to my family, Mimi Grozinger, Ken Grozinger, Kim Smith, and Kyle 
Grozinger for your support, encouragement, and love throughout the completion of my 
research. Thank you to my friend, Travis Gitau, for guidance and encouragement at all 
times. 
Lastly, I would like to thank the School of Graduate Studies, Faculty of Medicine, 
and CIHR for their financial support as a graduate student. 
. 
lV 
TABLE OF CONTENTS 
ABSTRACT ................................................................................. .............................. ....... .. ii 
ACKN"OWLEDGEMENTS ............................ ............................. ......... ........ ..................... iv 
TABLE OF CONTENTS .... ................................................................. ........ ......... .............. v 
LIST OF TABLES .................................. ............................................. ........ ..................... vii 
LIST OF FIGURES ......................................................................................................... viii 
LIST 0 F ABBREVIATIONS ............. ..................... ................ ...... ........ ........... .......... .... .. .. X 
1. 0 INTR 0 D U CTI 0 N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
1.1 Eye Sight ..... ..................... ... ....... ... .......................................................... ............ 1 
1. 2 Ocular Vasculature ...... ........ .......... .......... .......... ...... ....... ..... ....... .... ... .................. 3 
1.3 Neovascular Retinopathies ................................................ ..................... ............ 4 
1.4 Molecular Pathways of Endothelial Permeability .... ..................................... ...... 8 
1. 4.1 Transcellular Permeability (Transcytosis) ...... .......... ............... ...... ....... ..... 8 
1. 4. 2 Paracellular Permeability (Paracytosis) ......................... ............... ...... .... 11 
1.5 Tubedown: Homeostatic Regulator of the Ocular Vascular Systems through 
Endothelial Permeability Regulation .... ........... ...................................... ........... ............ 12 
1. 5.1 Tube down, In Vitro ............................. .......................................... ................... 14 
1. 5. 2 Tube down, In Vivo ......................... .............................. ................ ........ ........... 16 
1. 6 Rationale for Project . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 7 
1.7 Hypothesis ....... .... ............................ ..................... ........... ........ ....... ...... ............. 21 
2.0 MATERIALS AND METHODS .... .................... ......... ....... ..... .... .... ...... ............. ........ 22 
2.1 Antibodies ........................................ ................ ................... ......... ... .... ... ... ........ 22 
2.2 Cell Culture .................... ....... ....... .. ...... ................... ................ .......................... 23 
2.3 In Vitro Transcription/Translation ............................ .......... ......... .......... ... ........ 24 
2.4 C-Src Purification ....... ............... .................................... ................... ................ 25 
2.5 Irnmunoprecipitation ........................ ....................... ............ .. ........... ........ ......... 25 
2.6 Western Blot Analysis ............................................................ ... ........ ............... 27 
2. 7 siRN" A Knockdown ........ ............ ... .......................... ...... ........ ........... ......... ........ 2 8 
2.8 Coverslip Preparation/Immunofluorescence Staining ......... ........... .......... .... ... . 29 
2.9 Transient Transfection GFP Quantitation ..................... ....... ............... .............. 30 
2.10 Transient Transfection Protein Quantitation ....................................... .............. 30 
2.11 Z0-1 Perimeter Quantitation .......................... ................................ ....... ... .. ..... . 31 
2.12 Data Analysis and Statistics ............ ..... ............ ............................. ............. ... .... 31 
2.13 Sequence Alignment Analysis ... ..... ....... ......... .............................. ...... ....... ....... 3 2 
3.0 RESULTS ........... .............. ... ...................... ........................................................ ... 33 
3.1 Specificity of Tubedown Antibodies ............. .............. ..... ................. .............. 3 3 
3.2 Analysis ofTubedown/Dynarnin Interaction ....... .. ........... ............... ... ............ .. 36 
3.3 Analysis ofTubedown/AF-6 Interaction ....... ...................... ........................ .. ... 38 
3.4 Analysis ofTubedown/Y421-Phospho-Cortactin Interaction .... ...... ................ 40 
3.5 Analysis of Tubedown/c-Src Interaction .................... ..................... ............. .... 45 
3.6 Analysis ofTubedown/Z0-1 Interaction ........ .............. .................................... 53 
3. 7 Analysis of Z0-1 Distribution in Tubedown Knockdowns ................ ...... ...... .. 54 
4.0 DISCUSSION ........... ......... ...... ......... ....... .. ................... ....... ...... ......... .......... .......... .... 65 
v 
5 . 0 SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 9 
6.0 REFERENCES .................................................................. ................ ........ ........... ...... 80 
Vl 
LIST OF TABLES 
Table 2. 1 Antibody Inventory ...................................................................................... 22 
Vll 
LIST OF FIGURES 
Figure 1. 1 Schematic Depicting Structures of the Eye ................................................ 2 
Figure 1. 2 Transcellular and Paracellular Permeability: Molecular Interactions in 
1H:Ild()th~li~l ~~lis ....................................................................................................... ~ 
Figure 1. 3 Structural Domains of Tubedown ............................................................. 13 
Figure 3. 1 Specificity of Tubed own Antibodies ......................................................... 35 
Figure 3. 2 Dynamin and Tubedown: Western Blot Analyses ofTubedown 
Immunoprecipitation .............................................................................................. 37 
Figure 3. 3 AF-6 and Tubedown: Western Blot Analyses ofTubedown 
Immunoprecipitation .............................................................................................. 3~ 
Figure 3. 4 Y421-Phospho-~ortactin and ~ortactin: Western Blot Analyses of 
~ortactin Immunoprecipitation ................................................•........................... 43 
Figure 3. 5 Y421-Phospho-~ortactin, ~ortactin, and Tubedown: Western Blot 
Anaylses of Tubedown Immunoprecipitation ...................................................... 44 
Figure 3. 6 Tubed own and c-Src: Western Blot Analyses of Tubed own 
Immunoprecipitation .............................................................................................. 4~ 
Figure 3. 7 Tubedown and c-Src: Western Blot Analyses of Tubedown ................... 50 
Figure 3. 8 Tubedown and c-Src: Western Blot Analyses of c-Src and Myc-Tag 
Immunoprecipitations ............................................................................................ 51 
Figure 3. ~ Tubed own, c-Src, and Ard1: Photon Emissions and Western Blot 
Analysis of 35S-Tubedown-Myc-His and 35S-Ardl-Myc-His 
Immunoprecipitations Incubated with Purified c-Src ......................................... 52 
Figure 3. 10 Z0-1 and Tubedown: Western Blot Analyses of Z0-1 
Immunoprecipitation .............................................................................................. 56 
Figure 3. 11 GFP Transfection Efficiency in Transiently Transfected RF /6A 
1H:11d()th~li~l ~tells .................................................................................................•... 57 
Figure 3. 12 Tubedown and Tubulin: Western Blot Analyses of W~L from 
Transient Tubedown Knockdowns ....................................................................... 58 
Vlll 
Figure 3. 13 Quantitative Analysis: Tube<lo~n Expression in Transient Tube<lo~n 
~ll()~~(l()~llS. ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• :;~ 
Figure 3. 14 Z0-1 an<l Tubulin: Western Blot Analyses ofWCL from Stable an<l 
Transient Tubedo~n Knoc~do~ns ....................................................................... 60 
Figure 3. 1:; Quantitative Analysis: Z0-1 Expression in Transient Tubedown 
~ll()~~d()WilS •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 6JL 
Figure 3. 16 Quantitative Analysis: Z0-1 Expression in a Stable Tubedo~n 
~()e!~d()~ll Cl()lle! ................•..•..••••.••••..•.••..................••...••...........•............•...........• 6~ 
Figure 3. 17 Fluroescent Staining: Z0-1 Distribution in Stable and Transient 
Tu bedo~n Knoc~downs ......................................................................................... 63 
Figure 3. 18 Z0-1 Cell Perimeter Quantitation of Stable and Transient 
Knoc~do~ns of Tubedo~n ..................................................................................... 64 
Figure 4. 1 BLAST Analysis of Control siRNA and MMP20 Homology .................. 72 
Figure 4. ~ BLAST Analysis of Control siRNA and P2RY12 Homology ................. 72 
Figure 4. 3 Hypothesize<l Mechanism for Tube<lo~n's Regulation of Transcytosis 76 
. 
lX 
LIST OF ABBREVIATIONS 
Ab Antibody 
ADIP Afadin and a-actinin binding protein 
AF Afadin 
AJ Adherens junctions 
AMD Age-related macular degeneration 
Ardl Arrest defective protein 1 
ARP Actin related protein 
ASTB Antisense Tubedown 
BSA Bovine serum albumin 
BLAST Basic local alignment search tool 
oc Celsius 
c-Src Cellular Src 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco' s Modified Eagle Medium 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
GFP Green fluorescent protein 
gp60 60 kDa glycoprotein 
His Polyhistadine tag 
X 
HRP Horseradish peroxidase 
IEM Immortalized endothelial cells 
JAM Junctional adhesion molecule 
kDa Kilodalton 
MAG UK Membrane guanylate kinase-like homologue 
mAmp Milliamp 
~g Microgram 
ml Millimeter 
~1 Microliter 
mm Millimeter 
mM Millimolar 
~M Micromolar 
MMP Metallopeptidase proteins 
mNAT-1 Mouse N-terminal acetyltransferase 
Myc-Tag c-Myc epitope tag 
NATH N-acetyltransferase 1 protein 
NARG1 NMDA receptor regulated gene 1 
NEAA Non-essential amino acid 
Neo Neocin 
ng Nanogram 
NMDA N-Methyl-D-aspartate 
PDR Proliferative diabetic retinopathy 
. 
Xl 
PVDF Polyvinylidene fluoride 
ROP Retinopathy of prematurity 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SFK Src family kinase 
T -SNARES N-ethylmaleimide-sensitive factor attachment protein receptor family 
Tbdn Tubedown 
TBS Tris buffered saline 
TBST Tris buffered saline tween 
TJ Tight junction 
TnT Transcription and translation 
TPR Tetratricopeptide repeat 
VE-Cadherin Vascular endothelial Cadherin 
VEGF Vascular endothelial growth factor 
WCL Whole cell lysate 
y Tyrosine 
zo Zona occludens 
.. 
xu 
The Role of Tubed own in Ocular Endothelial Permeability 
1.0 INTRODUCTION 
1.1 Eye Sight 
The eye is a complex organ capable of receiving refractive light and commencing 
the energy exchange necessary to perceive an image. The formation of an image begins 
with light reflecting off the surface of an object entering the eye and passing through the 
cornea and lens optimizing it to be inversely projected onto the macula, the center of the 
retina (Pylyshyn et al. , 2003) [Fig. 1.1 ]. The retina is a multi-layered, light-sensitive 
tissue that lines the inner surface of the eye. It is located in-between the choroidal tissue 
and the vitreous humor. The retina is a highly regulated tissue containing rods, cones, 
bipolar, horizontal, amacrine, ganglion, and Muller cells (Kolb, 1995). These cells are 
responsible for converting light energy into chemical energy for transference to the visual 
cortex of the brain (Jackson et al., 2003 ; Roberts, 1995). Damage to the retina can inhibit 
the conversion of energy and consequently decrease visual acuity eventually leading to 
complete blindness. 
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Figure 1. 1 Schematic Depicting Structures of the Eye. 
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1.2 Ocular Vasculature 
The ocular vasculature plays a vital role in the clarity of eyesight. There are 
specific avascular and vascularized tissues within the eye, which must be maintained for 
optimum eyesight. The retina requires a constant supply of oxygen and nutrients from 
blood vessels in order for it to be functional. The inner retinal layers, closest to the 
vitreous humor, are vascularized while the outer layers of the retina, closest to the 
choroid, are relatively avascular (Wanek et al. , 2011). The retina receives the necessary 
nutrients and oxygen from two discrete circulatory systems. Fenestrated capillaries 
within the choroid allow for rapid diffusion of molecules to supply the outer retina with 
nutrients while the inner retina is supplied by the central retinal artery which branches out 
to supply the entire inner retina (Roh et al. , 201 0). 
The eye contains blood-ocular barriers that are much like the blood-brain barrier, 
which control the movement of molecules from within the vessel to the outer tissues. 
The two blood-ocular barriers include the blood-aqueous barrier and the blood-retinal 
barrier. Ciliary epithelium and capillaries of the iris control the blood-aqueous barrier 
(Wanek et al. , 2011 ). The blood-retinal barrier is controlled by tight-junctions between 
retinal endothelial and epithelial cells which comprise the inner and outer components of 
the blood-retinal barrier, respectively [Fig. 1.1] (Wanek et al. , 2011 ). The inner 
component of the blood-retinal barrier consists of tight junctions between endothelial 
cells lining the central retinal blood vessel located in the inner most part of the retina 
(Cunha-Vaz et al., 2010). The outer component of the blood-retinal barrier consists of 
tight junctions between epithelial cells that comprise the retinal pigment epithelium and 
3 
the most outer portion of the retina (Cunha-Vaz et al., 2010). Damage to the blood-
retinal barrier is associated with ocular neovascular diseases (Roh et al., 201 0). 
1.3 N eo vascular Retinopathies 
In, general vessel growth in healthy adults in restricted to periods of wound 
healing, hair growth, pregnancy, and menstruation (Witmer et al. , 2003). However, 
ocular angiogenesis, the process of growth of blood vessels, within a healthy individual 
ceases after birth (Chan-Ling and Stone, 1992). However, angiogenesis is commonly 
seen with diseases of the eye such as wet age-related macular degeneration (AMD), 
proliferative diabetic retinopathy (PDR), and retinopathy of prematurity (ROP). The 
pathological cascade of ocular angiogenesis begins with vasodilatation and increased 
permeability mediated by vascular endothelial growth factor (VEGF) (Nagy et al., 2007). 
Increased permeability causes the endothelium to undergo differentiation and 
proliferation (Dvorak et al., 1995). The extracellular matrix is then degraded by matrix 
metalloproteases (MMP) and urokinase-type plasminogen receptor, allowing the 
endothelial cells to migrate (Witmer et al. , 2003). These pathological consequences 
allow the endothelium to form tube-like structures, which generate the basement 
membrane of new vessels. 
In neovascular retinopathies areas of the eye undergo angiogenesis due to hypoxic 
stimuli or an imbalance between inhibitory and inducing angiogenic factors. The 
hypoxic stimuli and imbalanced inhibitory and inducing angiogenic factors are known to 
cause an increase in permeability of endothelial cells, which is known to lead to 
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angiogenesis (Fischer et al. , 1999; Nagy et al., 2007). These newly formed vessels are 
weak and can hemorrhage, leaking fluids into the eye that cause lesions, scar tissue build-
up, and retinal detachment that can lead to subsequent blindness. 
AMD left untreated is the leading cause of blindness in individuals age 65 and 
older (Age-Related Eye Disease Study Research Group, 2001). Dry and wet are the two 
forms of AMD with wet also being known as neovascular AMD. Dry AMD results from 
atrophy of the retinal pigment epithelium underlying the retina (Itoh et al. , 1999; Nowak, 
2006). Wet AMD is the more advanced and more threatening form of AMD (Nowak, 
2006). Wet AMD is caused by damage to the macula from abnormal vessel growth due 
to an imbalance of inhibitory vs. inducing angiogenic factors (Rajappa et al. , 201 0). The 
macula is the center of the retina containing the highest concentration of cone cells within 
the eye and is responsible for high resolution of vision (Kolb, 1995). In patients with wet 
AMD angiogenesis begins under the macula within the choroidal tissue and can extend 
into the retina damaging the outer blood-retinal barrier (Cunha-Vaz et al. , 201 0). 
Increased VEGF production followed by increased permeability of the endothelium 
causes a build-up of fluid under and in the retina (Ng and Adamis, 2005). In the early 
stages, patients begin seeing dark spots within their central vision and straight lines can 
become wavy; furthermore, wet AMD can advance to complete blindness within as little 
as three months (Wong et al., 2008). 
Diabetic retinopathy affects over 6 % of Canadians (Maberley et al. , 2006). 
Decreased retinal blood flow, inflammation, endothelial cell loss and capillary basement 
membrane thickening signify early stage diabetic retinopathy, also named 
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nonproliferative diabetic retinopathy. More advanced retinal ischemia causes 
pathological angiogenesis throughout the retina and is referred to as PDR (Durham and 
Herman, 2011). The neovascularization within PDR can cause damage to the inner 
blood-retinal barrier leading to increased permeability (Cunha-V az et al. , 201 0). Patients 
with PDR have hazy vision with dark spots, which can advance to complete blindness. 
Retinopathy of prematurity is a complication affecting 13 % of premature babies 
within the United States (Mataftsi et al., 2011 ). Healthy fetal ocular vessel growth begins 
in the optic disc at gestation week 18 and ends at full term on week 40. ROP occurs in 
two phases, the first is delayed vessel growth followed by uncontrolled vessel growth 
within the second phase. When a baby is born prematurely they are introduced to a 
hyperoxic environment more suddenly than a full term baby delaying normal 
neovascularization, the formation of microvascular networks. As a result, uncontrolled 
neovascularization occurs throughout the eye to compensate for the lack of oxygen. The 
uncontrolled vessel growth causes damage to the inner blood-retinal barrier leading to 
increased permeability (Chan-Ling and Stone, 1992). While ROP can be spontaneously 
repaired 40 % of infants are left with a moderate decrease in visual acuity, and 18 o/o 
develop severe ROP having possible retinal detachment and concurrent blindness 
(Phelps, 1995). 
Wet AMD, PDR, and ROP can all attribute vision loss to increased vascular 
permeability leading to vessel growth and leaky vessels damaging the blood-retinal 
barrier (Schlingemann and van Hinsbergh, 1997). Therefore, these diseases are all 
treated similarly with anti-angiogenic therapeutics. In early stages of wet AMD, PDR, 
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and ROP, surgery or photodynamic therapy may be used. However, in advanced stages 
anti-angiogenics are now the most effective therapeutic for all three diseases whether it is 
alone or in combination with other treatments (Meyer and Holz, 20 11; Orozco-Gomez et 
al., 2011; Age-Related Eye Disease Study Research Group, 2001; Bressler, 2009). The 
most effective anti-angiogenic therapeutics target the VEGF protein or receptor (Bayes et 
al., 2002). VEGF is a key mediator of vessel growth that stimulates increased endothelial 
cell migration, permeability, and survival. Therefore, in order to decrease side effects at 
normal vascularized beds, anti-angiogenic drugs are directly injected into the eye. 
Intravitreal injections can lead to adverse effects such as corneal abrasion, ocular 
inflammation and 1.5 % of patients have consequential injury to the lens or complete 
retinal detachment (Shima et al., 2008; Simo et al., 2008). Several reports have showed 
that as high as 17 % of patients who receive anti-angiogenic intravitreal injections have 
retinal pigment epithelial tears that subsequently decrease visual acuity (Chang et al., 
2007; Nicolo et al. , 2006; Yeh and Ferrucci, 2011). Anti-angiogenic treatments can pass 
into the blood stream leading to possible side effects of hypertension, proteinuria and 
cardiovascular events (Simo et al., 2008). Moreover, after 2 years of treatment with anti-
angiogenics, some patients no longer respond to therapy (Rosenfeld et al. , 2011). 
Enhancements to anti-angiogenic therapeutics that avoid intravitreal injections could be 
achieved by targeting other regulators of the permeability pathway that are specific to the 
retina. In addition, therapies that address the underlying physiological cause of 
neovascular retinopathies could aid in repairing damage to the retina and prevent loss of 
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visual acuity. Therefore, defining the mechanisms leading to abnormal 
neovascularization of the eye is pertinent to develop new therapies. 
1.4 Molecular Pathways of Endothelial Permeability 
The endothelium is a semi-permeable barrier lining all vessels within the body, 
and controls the fluid and solute exchange between the blood and surrounding tissues. 
Permeability of the endothelium is required for endothelial cells to receive nutrients and 
eliminate metabolic waste products. However, disruption of endothelial cell homeostasis 
leading to hyper-permeability is a known cause of pathological angiogenesis (Dvorak et 
al., 1995). Transcellular and paracellular are the two types of endothelial permeability 
[Fig.2]. Transcellular permeability (transcytosis) is movement of molecules through a 
cell. Paracellular permeability (paracytosis) is the movement of molecules between cells. 
1.4.1 Transcellular Permeability (Transcytosis) 
Transcytosis is selective to macromolecules such as albumin, albumin-bound 
ligands, hormones, insulin, and lipids (Komarova and Malik, 201 0). Transcytosis begins 
with a macromolecule binding to its corresponding receptor initiating endocytosis [Fig. 
1.2]. Endocytosis involves a flask-like invagination at the cell membrane of endothelial 
cells being formed and cinched off, creating a lipid bilayer raft known as a vesicle. The 
vesicle is actively transferred to the other side of the cell where it undergoes exocytosis. 
Exocytosis is the process of a vesicle docking and fusing onto the baso-lateral membrane, 
thereby releasing its contents into the surrounding tissues. Vesicles may be coated in 
caveolin or clatherin protein. Within endothelial cells caveolin-coated rafts known as 
8 
Vessel 
0 
0 0 
Figure 1. 2 Transcellular and Paracellular Permeability: Molecular Interactions 
in Endothelial Cells. Transcytosis is initiated by albumin (A) binding to gp-60 and 
Caveolin-1 (C-1) oligimerization at the plasma membrane. C-Src tyrosine kinase 
phosphorylates Cortactin and Dynamin-2 enhancing their interaction required for 
transcytosis. Dynamin-2 (D-2) wraps around neck of caveolae cinching them from the 
membrane and creating a vesicle. Cortactin bound to the actin cytoskeleton advocates 
endocytosis and caveolae transport from the apical to basal side of the endothelial cell. 
The caveolae undergo exocytosis and its contents are released into the surround 
tissues. In paracytosis Z0-1 recruits the inter-endothelial junctional proteins VE-
cadherin, JAM and Occludin to the plasma membrane which bind to the actin 
cytoskeleton restricting the passage of solutes larger than 3 nm. 
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caveolae comprise over 97 o/o of vesicular transport (Predescu et al., 2007). The 
transcytotic signaling cascade is best defined by the caveolae exclusive transport of 
albumin. The transcytosis of albumin begins with its binding to one of its cell surface 
receptors, such as glycoprotein-60 (gp-60), followed by the cytosolic monotropic 
membrane protein Caveolin-1 oligomerization at the cell membrane (Vogel et al., 2001) 
[Fig. 1.2]. Oligomerization ofCaveolin-1 enables the formation of the flask-like 
invagination of the membrane (Minshall et al., 2002). The interaction between the 
guanosine triphosphate-ase (GTPase) protein Dynamin-2 and actin-bound Cortactin at the 
cell membrane regulates actin reorganization aiding in the formation of the invagination 
(Schafer et al. , 2002). Once the invagination is formed Dynamin-2 wraps around the 
neck separating the vesicle from the membrane (Jones et al., 1998). The cargo within the 
caveolae is then shuttled from the apical side of the cell to the basal side of the cell. The 
transport of caveolae from apical to basal surface of the endothelial cell is process that 
requires Src family kinases (SFK) and Cortactin (Shajahan et al. , 2004; Zhu et al. , 2007). 
The caveolae then undergoes exocytosis, which requires syntaxin and target soluble N-
ethylmaleimide-sensitive factor attachment protein receptor family (t-SNARES) 
(Littleton et al. , 1998). Furthermore, phosphorylation of Caveolin-1 and Dynamin-2 by 
c-Src, a member of SFK, facilitates transcytosis and initiates vesicle fission (Hu et al. , 
2008). In addition, c-Src phosphorylation of Dynamin-2 and Cortactin enhances their 
interaction with each other that is required for transcytosis (Cao et al., 201 0). 
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1.4.2 Paracellular Permeability (Paracytosis) 
Paracytosis is controlled by inter-endothelial junctions bound to the actin 
cytoskeleton, which form a barrier restricting passive diffusion of solutes larger than 3 
run in-between cells. There are two types of endothelial junctions, adherens junctions 
(AJ) and tight junctions (TJ) [Fig. 1.2]. AJ s are the more predominate junction within 
endothelial cells (Mehta and Malik, 2006). AJs are largely comprised of vascular 
endothelial cadherin (VE-cadherin) (Dejana et al. , 2008). VE-cadherin homophilically 
binds creating cell-cell adhesion between cells (Chappuis-Flament et al. , 2001). The 
cytoplasmic tail of VE-cadherin contains a highly conserved cadherin domain that binds 
alpha and beta-catenins, which are in tum bound to the actin cytoskeleton (V estweber et 
al. , 2009). Reorganization of the actin cytoskeleton can stabilize or destabilize AJs 
(Dudek and Garcia, 2001 ). TJ s are composed of the membrane spanning proteins 
Occludin, Claudin, and Junctional Adhesion Molecule (JAM). TJ proteins bound to the 
actin cytoskeleton are critical for regulation of paracytosis. 
An essential protein that is part of both AJ and TJ in paracellular permeability is 
Zona Occludins-1 (Z0-1 ). Z0-1 is required for both the formation of AJs and as a 
scaffold protein for the arrangement ofTJs, thereby playing a pivotal role in paracellular 
barrier function in endothelial cells (Umeda et al. , 2004; Ikenouchi et al., 2007). Z0-1 , -
2, -3 are a subfamily of membrane guanylate kinase-like homologue (MAG UK) family 
(Umeda et al. , 2006). The ZO subfamily has one Src homology 3 domain (SH3), one 
guanylate kinase-like domain (GuK), and three PDZ domains (Umeda et al., 2006). The 
SH3 and GuK domains of Z0-1 bind actin, AF -6, and Alpha-Catenin, and are critical for 
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Claudin polymerization. Z0-1 ' s interaction with actin, AF -6 and Alpha-Catenin allows 
for the transduction of extracellar signal, provides mechanistic stability, recruits proteins 
to TJ' s to regulate cell-cell contacts, and links AJs to the actin cytoskeleton for stability 
(Yamamota et al., 1997; Ebnet et al. , 2000; Rimm et al., 1995). Claudin polymerization 
is involved in TJ formation and Z0-1 is necessary for the location of Claudin 
polymerization (Umeda et al., 2006; Furuse et al. , 1999). The PDZ domain within Z0-1 
is named because post synaptic density protein, Drosophila disc large tumor suppressor, 
and Z0-1 were the first three proteins in which the domain was discovered (Kennedy et 
al. , 1995). The PDZ domain of Z0-1 interacts with all three membrane proteins that 
form TJs; Occludins, Claudins, and JAMs (Itoh et al. , 1999; Furuse et al. , 1994; Bazzoni 
et al. , 2000). 
1.5 Tubed own: Homeostatic Regulator of the Ocular Vascular Systems through 
Endothelial Permeability Regulation 
Mammalian homologues of the Tubedown protein were first reported in the year 
2000 (Gendron et al. , 2000). In the literature, Tubedown may also be referred to as 
mouse N-acetyltransferase 1 (mNat1 ), N-acetyltransferase human (NATH), or N-methyl-
D-aspartate receptor regulated gene 1 (NARG 1 ). However, it has recently been renamed 
Naa15 (N-alpha-acetyltransferase 15) (Polevoda et al., 2009). Tubedown exists mainly 
as a 1 00 kDa isoform, containing three tetratricopeptide repeat (TPR) motifs, a linker 
region, and a syntaxin-18 homology domain [Fig. 1.3] (Gendron et al. , 2000; Dr. H. 
Paradis [Memorial University ofNewfoundland], personal communication (Gendron et 
al. , 2000; Mullen et al. , 1989). In yeast, Nat1 is known to interact with arrest-defective 
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Figure 1. 3 Structural Domains of Tubedown. Tubedown contains 3 
tetratricopeptide repeat (TPR) structural motifs, a linker region, and a syntaxin-18 
homology domain (Dr. H. Paradis [Memorial University of Newfoundland], personal 
communication). 
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protein 1 (Ard1) and form an essential part of the NatA complex, which conducts N-
terminal a-acetylation on nascent polypeptides protruding from the ribosome (Park and 
Szostak, 1992). Tubedown has also been shown to interact with Ard1 , co-purify with 
acetyl transferase activity within mammalian cells, and Ard 1 is co-downregulated with 
Tubedown (Paradis et al., 2008; Arnesen et al. , 2005; Gendron et al., 2000). While 30 % 
of mammalian proteins are acetylated, the outcome of acetylation is it still not completely 
understood (Meinnel et al., 2005). Post translational modifications like N-terminal a-
acetylation has many molecular consequences. For example, N-terminal a-acetylation 
can stimulate the degradation of a protein or protect a protein from degradation (Arnesen 
et al. , 2009; Min et al. , 201 0). Tubedown is transiently expressed during embryogenesis 
in the developing endothelium and vasculature (Gendron et al., 2000). In adults, 
expression is limited to the endothelium of a few vascular beds with highest expression 
seen in the ocular vasculature (Gendron et al. , 2000; Gendron et al. , 2001). A second 
human isoform of Tubedown exists having an 81 % similiarity with the primary human 
isoform of Tubedown (Arnesen et al., 2009; Sugiura et al., 2003). 
1.5.1 Tubedown, In Vitro 
Stable knockdown retinal-choroidal endothelial cell clones ofTubedown (ASTB) 
generated with an antisence eDNA fragment in Drs. Paradis and Gendron' s laboratory 
(Memorial University of Newfoundland in St. John' s, NL) have a ---50 % decrease in 
Tubedown expression (Paradis et al., 2002). The ASTB lines were generated in rhesus 
macaque retinal-choroidal endothelial cells (RF/6A). In vitro, Tubedown suppression 
leads to increased capillary formation in both the RF /6A endothelial cell clones and an 
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immortalized murine endothelial cell (IEM) clonal line (Paradis et al. , 2002; Gendron et 
al. , 2000). Tubedown suppression showed increased permeability to both albumin and 40 
kDa-dextran which are transported by transcytosis and paracytosis, respectively (Paradis 
et al., 2008; Dr. H. Paradis [Memorial University of Newfoundland], personal 
communication). In addition, Asaumi et al. found that co-expression of mammalian 
Tubedown and Ard 1 suppressed transcytosis of the Alzheimers ~-amyloid precursor 
protein (2005). In vitro, work with Tubedown provides evidence that Tubedown 
regulates ocular endothelial permeability. 
To explore the mechanism in which Tubedown may regulate endothelial 
permeability co-immunoprecipitation and co-localization techniques were completed and 
Tubedown was found to interact with the actin-binding protein Cortactin (Paradis et al. , 
2008). Cortactin is known to regulate F -actin polymerization through its interaction with 
actin-related protein 2 and 3 complex (Arp2/3) (Uruno et al. , 2001). Alterations to the 
actin-cytoskeleton are known to change endothelial cell shape which can alter inter-
endothelial junctions leading to increased permeability (Osborn et al. , 2006; Dudek and 
Garcia, 2001 ). Actin-cytoskeleton reorganization by Cortactin is required for membrane 
internalization which is essential for vesicle formation in transcytosis (Zhu et al., 2007). 
Preliminary studies have shown decreased Tubedown expression may be linked to 
an increase in tyrosine 416 (Y 416)-Phospho-Src, a member of Src family kinase family 
(SFK), in endothelial cells (Whelan, 2011 ). In humans, the normal cellular protein for 
Src is referred to as cellular Src (c-Src). Y416 and Y527 are two significant sites on c-
Src that can be phosphorylated and control its activation. C-Src is activated with 
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phosphorylation at Y 416 or by dephosphorylation of Y527 (Schlessinger, 2000). 
Therefore, Tubedown seems to be regulating the activation of c-Src. Currently, further 
characterization of decreased Tubedown expressions affect on Y 416-phospho-Src is 
being carried out by another master' s student, Nhu Ho (Dr. H. Paradis [Memorial 
University of Newfoundland], personal communication). 
1.5.2 Tubedown, In Vivo 
In vivo, research with bitransgenic endothelial specific Tubedown knockdown 
mice show increased retinal albumin leakage, retinal and choroidal neovascularization, 
retinal thickening, and lesions within the retina (Wallet al. , 2004; Paradis et al. , 2008; 
Gendron et al. , 201 0). Furthermore, the pathological consequences seem to be restricted 
to the retina and choroid (Wallet al. , 2004). In vivo pathological features ofTubedown 
knockdown mice mimic the pathological features of human patients with wet AMD, 
PDR, and ROP. 
Patients with PDR and ROP show decreased Tubedown expression in the retinal 
vasculature correlating with the areas of pathological angiogenesis seen within patients 
(Gendron et al. , 2001 ; Gendron et al. , 2006). Patients with AMD show decreased 
Tubedown expression within the choroidal vasculature, which again parallels with the 
area of neovascularity observed in affected patients (Gendron et al. , 201 0). The 
cumulative evidence suggests that Tubedown is regulating ocular endothelial 
permeability and therefore ocular vascular homeostasis; however, Tubedown' s 
mechanistic role in the regulation of endothelial permeability remains incompletely 
understood. 
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1.6 Rationale for Project 
Suppression of Tubedown causes increased retinal-choroidal endothelial 
permeability and angiogenesis. Tubedown interacts with the actin-binding protein 
Cortactin which is known to regulate both paracellular and transcellular permeability. 
Tubedown shows marked suppression in AMD, PDR, and ROP in correlation with areas 
of increased permeability and vascularity seen in patients (N g and Adamis, 2005; Cunha-
Vaz et al., 2010; Chan-Ling and Stone, 1992). It is a possibility that decreased 
Tubedown expression is the underlying cause or mechanistic outcome observed in ocular 
neovascular diseases. There have been no reported mutations in Tubedown; however, a 
human mutation in the Tubedown binding protein Ard 1 has been shown to cause severe 
developmental defects ultimately due to reduced protein acetylation (Rope et al. , 2011 ). 
Therefore, it is possible that Tubedowns role in the acetylation complex with Ard 1 plays 
a role in the developmental defects seen with Ard 1 mutations. 
TPR motifs are known to act as interaction scaffolds in a range of cellular 
processes including protein translocation (Allan and Ratajczak, 2011). Since Tubedown 
contains three TPR motifs I was interested in protein interactions Tubedown might have 
with other prominent regulators of the permeability pathways: Dynamin, AF -6, Y 421-
Phospho-Cortactin, c-Src, and Z0-1 . 
Dynamin is a large GTPase that regulates endocytosis in transcellular 
permeability. Dynamin can independently catalyze fission of the membrane in 
endocytosis by wrapping around the neck of a vesicle. Dynamin contains a GTPase 
domain, a pleckstin homology domain, a GTPase effector domain, and a proline-rich 
17 
domain (Low and Lowe, 2010). There are three mammalian forms ofDynamin that each 
have distinct expression patterns: Dynamin-1 is neuronal-specific, Dynamin-2 is 
ubiquitously expressed and Dynamin-3 is expressed in testis, lung, and brain (Cook et al. , 
1996). Therefore, only Dynamin-2 is expressed within the ocular endothelium. Since, 
Dynamin-2 is a key transcellular regulator it was hypothesized to be a potential binding 
partner with Tubedown. 
Afadin (AF -6) localizes to adherens junctions, is required for the Z0-1 
recruitment to nectin-based AJ s and is essential for structural organization of both AJ s 
and TJs (Mandai et al. , 1997; Yokoyama et al., 2001; Ikeda et al. , 1999; Zhadanov et al. , 
1999). Previous liquid chromatography mass spectrometry analysis revealed that the 
afadin dilute domain-interacting protein (ADIP), an afadin- and a-actinin-binding 
protein, had high identity with a protein that co-immunoprecipitated with Tubedown (Dr. 
H. Paradis [Memorial University of Newfoundland], personal communication). While 
ADIP' s role is poorly characterized, it is known to take part in platelet derived growth 
factor-induced cell movement that requires AF-6' s interaction (Fukumoto et al. , 2011). 
We speculated that AF -6 and Tubedown might interact. Therefore, co-
immunoprecipitation in combination with western blotting techniques were used to test 
this hypothesis. 
While Tubedown and Cortactin bind, no work has shown how Cortactin 
phosphorylation affects their interaction. Cao et al. recently showed that c-Src tyrosine 
phosphorylation of Cortactin was necessary for efficient transcytosis of transferrin (Cao 
et al. , 201 0). Lambotin et al. also showed in 2005 that phosphorylation of Cortactin is 
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necessary for incorporation of the Neisseria meningitides into endothelial cells (Lambotin 
et al., 2005). These results along with others suggest phosphorylation of Cortactin 
enhances transcellular permeability (Huang et al., 1998; Yang et al. , 2006). Cortactin can 
be phosphorylated by proteins such as Rae, myosin light-chain kinase, and extracellular 
signaling-regulator kinase; however, most well studied is tyrosine phosphorylation by c-
Src (Lua and Low, 2005). Cortactin phosphorylation by c-Src occurs at tyrosine residues 
421 , 466, and 482 (Huang et al. , 1998). C-Src phosphorylation of Cortactin has been 
linked to increased actin assembly and polymorphonuclear leukocyte transmigration 
(Tehrani et al., 2007; Yang et al. , 2006). Furthermore, c-Src phosphorylation of 
Cortactin at tyrosine residues is progressive whereby Y 421 precedes Y 466 
phosphorylation (Head et al. , 2003). Since tyrosine phosphorylation of Cortactin is 
important for its function in regulating transcytosis, it would be important to determine if 
phosphorylated Cortactin, at c-Src specific Y 421 , binds Tubedown. Co-
immunoprecipitation and western blotting techniques were used to determine whether 
Y 4 21-Phospho-Cortactin and Tubedown interact. 
C-Src is a member of SFK, which are non-receptor cytoplasmic membrane 
associated tyrosine kinases (Hu and Minshall, 2009). C-Src plays a critical role in 
transendothelial permeability by acting as a ' switch' to regulate caveolar transport (Hu 
and Minshall, 2009). For example, c-Src is known to phosphorylate Caveolin-1 and 
Dynamin-2 enhancing their interaction and initiating vesicle fission (Hu et al. , 2008). In 
addition, as mentioned above, c-Src is known to phosphorylate Cortactin and lead to 
increased permeability (Tehrani et al., 2007; Yang et al., 2006). Recently, it was found 
19 
that decreased Tubedown expression may correlate with an increased quantity of Y 416-
Phospho-Src within endothelial cells (Dr. H. Paradis and N. Ho [Memorial University of 
Newfoundland] , personal communication; (Whelan, 2011). Currently, another master's 
student has taken on the project of confirming if decreased Tubedown expression 
correlates with increased Y416-Phospho-Src in vivo. Since c-Src is known to play such a 
critical role in transcellular permeability, I hypothesized that Tubedown may be 
regulating transcellular permeability through an interaction with c-Src. Co-
immunoprecipitation and western blotting techniques were used to determine whether c-
Src and Tubedown interact. 
Z0-1 has been shown to recruit inter-endothelial junctions to the membrane, bind 
numerous permeability regulators, and is involved in maintaining the structure of 
paracellular permeability proving it to be a key regulator of paracellular permeability 
(Umeda et al., 2004; Ikenouchi et al. , 2007; Yamamoto et al., 1997; Ebnet et al., 2000; 
Rimm et al. , 1995). Electron microscopy of tight junctions within the retinal-blood 
barrier show extensive amounts of ZO (Cunha-Vaz, 1976). Z0-1 is known to interact 
with the Tubedown binding partner Cortactin (Katsube et al, 1998). Since Z0-1 plays 
such an important role in paracellular permeability, it was speculated that Tubedown 
might bind Z0-1 . Again, immunoprecipitation followed by western blotting techniques 
were used to test this hypothesis. In addition, previous unpublished work in Drs. 
Gendron and Paradis' laboratory has shown decreased Z0-1 cell perimeter expression 
with immunofluorescence in ASTB clones (Dr. H. Paradis [Memorial University of 
Newfoundland] , personal communication). These results suggest that Tubedown may 
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recruit Z0-1 to inter-endothelial junctions to regulate paracellular permeability. 
However, further validation was needed to prove Tubedown's involvement in the 
regulation of Z0-1 perimeter expression. A transient Tubedown knockdown protocol 
was developed for the RF /6A endothelial cell line for comparison with the stable 
Tubedown knockdown ASTB cell clone for further investigation ofTubedown's influence 
over Z0-1 expression at the cell membrane. 
1. 7 Hypothesis 
I hypothesize that Tubedown is interacting with other protein regulators of the 
permeability pathways to decrease endothelial cell permeability: Dynamin-2, AF-6, 
Y 421-Phospho-Cortactin, c-Src, and Z0-1. In addition, I hypothesize that Tubedown 
may be regulating the endothelial permeability pathways through relocation Z0-1 to the 
cell membrane. 
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2.0 MATERIALS AND METHODS 
2.1 Antibodies 
T bl 2 1 A fb d I t a e • n 1 o tv nven orv 
APPLICATION 
Antibody Target Origin 
WB IP IF 
Rabbit Polyclonal Tubed own X X Custom LE C10-20 (Paradis et al., 2007) 
Rabbit Polyclonal Tubed own X X Custom MI-C755 (Paradis et al., 2007) 
Mouse Monoclonal Tubed own X X Santa Cruz Bio. Inc. Nar21 (Santa Cruz, CA) 
Mouse Monoclonal AF-6 X X Santa Cruz Bio. Inc. AF-6 (Santa Cruz, CA) 
Mouse Monoclonal Cortactin Upstate Cell Signaling 
Cortactin (p80/85) (clone X X Solution (Lake Placid, 
4F11) NY) 
Rabbit Polyclonal Y 421-Phospho- X Cell Signaling Tech. Y 421-Phospho-Cortactin Cortactin (Pickerin2, Ontario) 
Mouse Monoclonal Dynamin X BD Transduction Lab. Dynamin (Lexin2ton, KY) 
Mouse Monoclonal Z0-1 X X X Invitrogen Z0-1 (clone 1A12) (Carlsbad, CA) 
Mouse Monoclonal Z0-1 X Santa Cruz Bio. Inc. Z0-1 (clone R40. 76) (Santa Cruz, CA) 
Rhodamine Red-X Primary Antibody Jackson Immuno 
Anti-Mouse Conjugate X Research Lab. Inc. 
(West Grove, PA) 
Negative Control Anti- Primary Antibody X X Dako Mouse lgGt (Mississauga, Ontario) 
Anti-Mouse IgG HRP Primary Antibody X Pro mega (Fitch ber2, WI) 
Anti-Rabbit IgG HRP Primary Antibody X Pro mega (Fitchberg, WI) 
Mouse Monoclonal Tubulin X Sigma Tubulin (clone DM1A) (St. Louis, M 0) 
Anti-Myc Tag Myc Tag X X Millipore (Clone 4A6) (Billerica, MA) 
Anti-Mouse c-Src c-Src X X Abeam (clone 327) (Cambridge, MA) 
*Western Blot (WB), Immunoprecipitation (IP), Immunofluorescence (IF), 
Horseradish peroxidase (HRP) 
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2.2 Cell Culture 
RF/6A endothelial cells are immortalized rhesus macaque choroid-retinal endothelial 
cells which were originally obtained from American Type Cultlire Collection. RF /6A 
endothelial cells were cultured in low glucose Dulbecco' s Modified Eagle Media 
(DMEM) (Invitrogen) supplemented with 10 % of heat inactivated fetal bovine serum 
(FBS), 50 J.!M non-essential amino acids (NEAA), and 2 J.!M glutamine. The ASTB 
clones created previously with a pcDNA/Zeo 3.1 antisense construct designed to 
knockdown Tubedown expression have previously been described (Paradis et al., 2002). 
The ASTB clones from RF /6A endothelial cells were cultured in the same manner as the 
parental RF /6A endothelial cells with the addition of 100 }.!g/ml of Zeocin to maintain 
expression of the transgene. The RF/6A Tubedown-Myc-His and Ard1-Myc-His clones 
created previously were designed with a pcDNA/Neo/Myc-His 3.1 vector containing 
either Tubedown or Ardl coding sequences, respectively (Dr. H. Paradis [Memorial 
University ofNewfoundland], personal communication). The RF/6A Tubedown-Myc-
His and Ard1-Myc-His clones were cultured in the same manner as parental RF/6A 
endothelial cells with the addition of 300 }.!g/ml and 750 }.!g/ml ofNeocin to maintain 
expression of the transgenes, respectively (Dr. H. Paradis [Memorial University of 
Newfoundland], personal communication). 
Immortalized mouse embryonic endothelial (IEM) cells were obtained and cultured as 
previously described (Gendron et al., 2000). IEM cells were cultured in the same manner 
as the RF/6A endothelial parental cells without adding NEAA. All cells were maintained 
at 3 7 oc in an atmosphere containing 1 0 % C02. 
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RF/6A parental and cell clones were plated at 0.75 x 106 cells per 100 mm plate 
for 48 hours of cell growth. IEM cells were plated at 1.5 x 106 cells per 100 mm plate for 
48 hours of cell growth. At the time of collection, cells were washed with cold tris-
buffered saline (TBS) containing 50 mM Tris-hydrochloric acid pH 7 .6, 150 mM NaCl, 
treated with a protein lysis buffer (50 mM Tris pH 7.6, 150 mM NaCl, 0.5 o/o Brij 96) 
with protease and phosphatase inhibitors (1 mM Sodium Orthovanadate, 0.3 U/ml 
Aprotinin, 10 J..Lg/ J..Ll Leupeptin, 1 mM Phenylmethylsulfonyl fluoride (PMSF), 25 mM 
NaF, 10 mM ~-glycerophosphate). Whole celllysates were agitated on a rotating stage at 
4 oc for 1 hour, centrifuged for 10 minutes at 4 oc at 10,000 X g, and supernatant 
collected. Protein was then quantified using Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Hercules, CA) using bovine serum albumin as standard and protein extracts 
were frozen at -80 °C until assayed. 
2.3 In Vitro Transcription/Translation 
TnT Quick Coupled Transcription/Translation System from Promega was used to 
transcribe and translate two different pcDNA3.1/Neo/Myc-His vectors (Invitrogen) that 
harbor either Tubedown or Ardl coding sequences (provided by Dr. H. Paradis) to 
generate 35S-labeled Tubedown and Ard1 , respectively. 35S-labeled protein samples were 
generated using 40 J.!l TnT Quick Master Mix, 4 J.!l e5S]-methionine/cysteine (11 
mCi/mL, Perkin Elmer (Santa Clara, CA)), 1 J..Lg plasmid, and 5 J.!l diethylpyrocarbonate 
(DEPC) treated H20. Samples were incubated at 30 oc for 90 minutes while gently 
mixing every 30 minutes. This method generated Myc-His tagged, 35S-labeled 
24 
Tubedown and Ard1 , respectively. Samples created using the 35S-labeled Tubedown and 
Ard1 TnT samples were run on 8% sodium dodecyl sulfate polyacrylamide gels (SDS-
p AGE) directly or used for immunoprecipitation (described below). Gels were then 
either transferred as described in Western Blot Analysis (Section 2.6) or dried using a gel 
dryer model 583 (Bio-Rad Laboratories, Hercules, CA). Dried gels or gels transferred 
onto nitrocellulose membranes were then exposed to small, multi-sensitive storage 
phosphor screen (Life Sciences, Boston, MA). Storage phosphor screens were exposed 
for 1 week to dried gels or nitrocellulose membranes, scanned with the Cyclone Storage 
Phosphor Scanner and analyzed with OptiQuant software version 03.10 from Life 
Sciences (Boston, MA). 
2.4 C-Src Purification 
Purified c-Src was a generous gift from Dr. N Lydon. In short, c-Src was purified 
by recombinant pp60c-Src baculovirus lacking the myristoylation site at codon 2 was 
transfected into Sf9 cells to produce non-myristoylated pp60c-Src (Lydon et al. , 1992). 
Non-myristoylated pp60c-Src was used to increase production and provide a more stable 
form of c-Src (Lydon et al., 1992). This method generates 95 % pure c-Src (Lydon et al. , 
1992). 
2.5 Immunoprecipitation 
All immunoprecipitation manipulations were conducted at 4 °C. Protein-G 
sepharose beads (Amersham, Buckinghamshire, England) were prepared by washing 2 X 
with 5 volumes ofTBS, and then twice with 5 volumes of 50 mM Tris-HCI pH 7.6, 150 
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mM NaCl, 0.5% Brij 96 (0.5 % TNB). A 50 % protein-G sepharose bead suspension was 
created with 0.5% TNB. Depending on recommended amounts for the antibody being 
used 500-1000 Jlg protein or 20 J..Ll 35S-labeled Tubedown-Myc-His or 35S-labeled Ard1-
Myc-His were used per immunoprecipitation. Samples were brought to a volume of 250 
Jll with 0.5 % TNB, and incubated overnight on a rotating stage at 4 °C. Antibody-
antigen complexes were mixed with 55 J..Ll50% Protein-G. Samples were centrifuged for 
1 minute at 1 000 X g and visualized for equal amounts of beads. Samples were then 
placed on rotating stage for 7 5 minutes, centrifuged for 1 minute at 1 000 X g and the 
supernatant aspirated. Beads were washed 4 X with 500 J..Ll of 0.5 % TNB. Supernatant 
was discarded and 12 J..Ll 5 X protein loading buffer (50 mM Tris- HCl (pH 6.7), 2% 
SDS, 10 % Glycerol, 1 % ~-mercaptoethanol, 12.5 mM Ethylenediaminetetraacetic acid 
(EDT A), 0.02 % Bromophenol Blue) was added. Samples were kept at 4 oc until 
electrophoresis. Bead-antibody-antigen complexes were boiled for 5 minutes at 100 °C 
before loading in 7 % SDS-PAGE. Immunoprecipitation of 35S-labeled proteins were 
analyzed on Cyclone Storage Phosphor Scanner as described above. 
Double and triple immunoprecipitations were performed using double and triple 
the amount of antibody, protein, and beads, respectively. All immunoprecipitations 
manipulations were completed as one and samples were split at the last wash for 
downstream application. 
26 
2.6 Western Blot Analysis 
Protein extracts were prepared as described previously in Cell Culture (Section 
2.2). Non-immunoprecipitation protein samples were prepared in 0.5 % TNB and boiled 
for 3 minutes at 100 °C. All samples were separated on a 7% SDS-PAGE overnight at 4 
mAmp. Gels were soaked in 25 mM Tris Base and 192 mM glycine for 15 minutes. 
Sponges, 0.2 J.lm nitrocellulose/PVDF membrane (Bio-Rad), and 3 MM whatman paper 
were soaked in 25 mM Tris Base, 192 mM glycerine, and 18 % methanol until saturated. 
Both nitrocellulose membranes (0.2 J.lm) and polyvinlidene fluoride (PVDF) membranes 
were used. Once transferred, membranes were placed into H20 for rinsing before being 
blocked in 2 % enhanced chemiluminescence (ECL) advance block (General Electric, 
Mississauga, Ontario) in TBS with 0.05 % Tween 20 (TBST), for 1 hour at 55 °C. 
Membranes were incubated overnight with primary antibody at room temperature in 2 % 
ECL advance block in TBST. Membranes were then washed 7 X for 5 minutes in 100 ml 
TBST, then incubated for 1.5 hours with a horseradish peroxidase (HRP) conjugated 
secondary antibody in 2 % ECL advance block in TBST. Membranes were again washed 
7 X for 5 minutes in TBST. Western blots were revealed by chemiluminescence that was 
detected using Lumiglo Reserve (Mandel, Guelph, Ontario), ECL Plus (Tubulin western 
blot analysis only) (General Electric), or ECL Advanced ( c-Src western blot analysis 
only) (General Electric) substrates based on antibody sensitivity and protein amounts. 
Images and densitometry analysis were performed using Kodak Gel Logic Imaging 
System (Eastman Kodak Company, Rochester, New York). Band intensities were 
analyzed with Kodak Molecular Imaging Software (Eastman Kodak Company). 
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To strip antibodies from the membrane in preparation for re-pro bing the 
membranes were placed in 60 mM Tris-HCl (pH 6.7), 2% SDS, 0.7%2-
mercaptoethanol, and 34 ml water for 1 hour at 55 °C. The membrane would then be 
washed 7 X for 5 minutes each in TBS before re-blocking the membrane for further 
western blot analysis. 
2.7 siRNA Knockdown 
RF /6A transient Tubedown knockdowns were formed by electroporation using a 
Neon Transfection Kit purchased from Life Technologies (Carlsbad, California). RF/6A 
endothelial cells were collected and counted with a hemocytometer after 24 hours of 
growth. Cells were then centrifuged and supernatant aspirated. Cell pellets were re-
suspended with 10 ml of sterile 3 7 oc phosphate buffered saline per 10 7 cells for 
washing. Suspensions were then centrifuged for 5 minutes at 150 X gat room 
temperature. Supernatants were aspirated and cell pellets re-suspended in sterile Buffer 
R (from Neon Transfection Kit) so that cells were at a final density of 1.33 x 106 
cells/110 J.!l Buffer R. Neon apparatus was assembled and 3 ml Buffer E2 (from Neon 
Transfection Kit) was added. Electroporation tubes from Neon Transfection Kit were 
replaced when different materials were electroporated or tubes had been used for 1 0 
electroporations. 
Cells were transfected with a combination of: 0-20 nM rhesus macaque 
Tubedown100 siRNA target Rhe-Tbdn703 (5 ' -TGCGAGATCTTGAGGGTTA-3') 
(Dharmacon, Lafayette, Colorado), 0-20 nM scrambled control siRNA SC47 (5 ' -
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GATCCGTTCATCGTCACT A-3 ' ) (Dharmacon, Lafayette, Colorado), 0.5 J.lg of plasmid 
maxFP-Green expressing a variant of the green fluorescent protein maxGFP (Amaxa 
Biosystems, Gaithersbury, Massachusetts), and 110 J.ll of Buffer R suspension plus cells 
(1.3 3 x 106 cells/sample). Electroporation was conducted with 2 pulses of 1150 volts and 
a pulse width of 30. These electroporation guidelines were determined to give the best 
maxFP-Green expression with low cell death using the RF/6A endothelial cell line. Once 
electroporated, samples were placed directly into RF/6A cell culture media, re-suspended 
and plated at 1.33 x 106 cells/100 mm plate or 0.3325 x 106 cells/well in 12-well chamber 
plate with 18 mm round glass coverslips at the bottom of each well. After 72 hours of 
cell growth plates and coverslips were retrieved. Whole celllysates from growth plates 
were prepared as described above in Cell Culture (Section 2.2) and protein quantitation 
conducted using Bio-Rad assay. 
2.8 Coverslip Preparation/Immunofluorescence Staining 
After 72 hours of growth wells from 12-well culture plates containing coverslips were 
washed 2 X with 1 ml cold TBS buffer. Coverslips were allowed to air dry then placed in 
4 % paraformaldehyde in phosphate buffered saline for 15 minutes and transferred into 
80 o/o ethanol for storage until staining was performed. Samples were not stored in 
ethanol at 4 oc for longer than 4 weeks to preserve antigenicity. 
For immunofluorescent staining coverslips were washed 2 X for 5 minutes in TBS 
and blocked for 1 hour at room temperature in 2 % ECL block (General Electric, 
Mississauga, Ontario) in TBS plus 0.2% TritonX-100 to permeabilize cell membranes. 
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Coverslips were then incubated with either Z0-1 (1A12) antibody at a 1:100 dilution or 
IgGt negative control antibody at 5 J.!g/ml in 2 % ECL block in TBST overnight at room 
temperature. Then coverslips were washed 3 X for 5 minutes in TBST before secondary 
antibody incubation with anti-mouse rhodamine red antibody at a 1:100 dilution in 2 o/o 
ECL block (General Electric, Mississauga, Ontario). Coverslips were washed 3 X for 5 
minutes each in TBST before being mounted with vectashield medium containing 4',6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, California) for 
nuclear detection. Coverslips were inverted onto clear slides and sealed with clear nail 
polish the next day. Fluorescence was visualized using the Leica DMIRE2 microscope 
with a brightfield 40 X objective using a Qimaging RETIGA Exi camera. Images were 
processed with Improvision Openlab software version 5.50. 
2.9 Transient Transfection GFP Quantitation 
Transient transfection efficiency was determined by visualizing cells after 72 hours of 
culture using the Leica DMIRE2 microscope with green fluorescent protein (GFP) and 
brightfield 10 X objectives using a Qimaging RETIGA Exi camera. Cells from a 20 rnm x 20 
rnm field from each image taken were counted and cells that expressed GFP were divided by 
total number of cells. A minimum of 20 cells from each transfection replicate were counted. 
2.10 Transient Transfection Protein Quantitation 
Tubedown and Z0-1 protein quantitation from transient transfections were conducted by 
visualizing western blot bands with a Kodak Gel Logic 2200 Imaging System followed by 
densitometric analyses of bands with Kodak Molecular Imaging Software 4.0. 
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2.11 Z0-1 Perimeter Quantitation 
Quantitation of cell perimeter Z0-1 expression was determined by counting cells that 
intensely expressed Z0-1 at the perimeter of the cell. Intensities were evaluated using 
Improvision Openlab Software version 5.50. Cells with less than an average of 60% contact 
with other cells were not counted due to decreased tight junction assembly at paracellular 
contacts (Siliciano, J.D. 1988). Cells undergoing mitosis or having mis-shaped nuclei were also 
not counted because this also could affect Z0-1 expression. No less than 100 cells per 
transfection group were quantitated for Z0-1 perimeter expression. 
2.12 Data Analysis and Statistics 
Statistical differences in data sets completed from quantitations were determined 
with analysis of variance between groups (ANOV A) using GraphPad Prism Version 4.0. 
Statistical differences of controls that were set to 100 % were determined using the T -test 
function of Microsoft Excel2008, version 12.2.0 with unadjusted numbers within each 
data set. While ANOVA is a more precise method when determining statistical 
differences between the means of multiple data sets, when the control is adjusted to 100 
o/o all data sets would then be statically different from the control. Therefore, T-test 
scores were completed from original values within individual data sets and the average 
used for accuracy of control comparison. Significant differences were considered for p < 
0.05 and are designated by an asterisk(*) within graphs. 
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2.13 Sequence Alignment Analysis 
The Basic Local Alignment Search Tool (BLAST) algorithm version 2.2.26+ was 
used to evaluate possible homologies with siRNA constructs (Altschul et al., 1990). 
Query sequences were 'BLASTed' into nucleotide BLAST (BLASTn) using the 
reference RNA sequences (refseq_ma) database accession Mmul_1 (Pruitt et al., 2009). 
Macaca mulatta was used as the organism because RF /6A endothelial cells are macae a 
mulatta derived. BLASTn automatically adjusts parameters to a short input sequence. 
Sequences showing a significant alignment were evaluated based on Expect (E) value 
that estimates the number of matches expected to occur randomly with a score equal to or 
higher than a given score. Simply put, the lower the E-value the greater chance of a 'hit' 
leading to siRNA interaction with an mRNA causing protein knockdown. The threshold 
of significance differs from study to study. Since short sequences were ' BLASTed' in 
this case an E value less than 15 was considered significant. After review of the E value 
protein matches were then further evaluated using Ensembl genome browser to determine 
significant regions within the protein. Genomic and siRNA input candidate sequences 
were aligned using Sequencher Software, version 4.1 0.1, from Gene Codes Corporation 
for visualization of homology. 
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3.0 RESULTS 
Testing potential Tubedown binding partners to elucidate its mechanistic role in the 
regulation of ocular endothelial permeability. 
3.1 Specificity of Tubed own Antibodies 
To confirm that the Narg1 commercial antibody recognizes the Tubedown 
protein, immunoprecipitations of 35S-labeled Tubedown-Myc-His transcription and 
translation (TnT) lysates were conducted with the Narg1 antibody. 35S-labeled 
Tubedown-Myc-His and 35S-labeled Ard1-Myc-His lysates were generated from 
transcription and translation (TnT) ofpcDNA3.1/Neo/Myc-His construct containing 
either Tube down or Ardl coding sequences, respectively. Immunoprecipitations using 
LE C 10-20 (Tubedown; Paradis et al., 2008) and Myc-Tag antibodies from 35S-labeled 
Tubedown-Myc-His lysates were used for comparison. Immunoprecipitation from 35S-
labeled Tubedown-Myc-His TnT lysate with no antibody was the control. 
Immunoprecipitations were exposed to phosphor screen and photon emissions analyzed. 
The photon emission band at 108 kDa in the Nargl immunoprecipitation proves that the 
Nargl antibody can immunoprecipitate Tubedown-Myc-His from 35S-labeled Tubedown-
Myc-His TnT lysates permitting it to be used for further analyses ofTubedown [Fig. 3.1]. 
35S-labeled Ardl-Myc-His TnT lysates were used as a positive control for 
comparisons to the Tubedown immunoprecipitations. Immunoprecipitations of 35S-
labeled Ard1-Myc-His TnT lysates were conducted using either the Myc-Tag antibody or 
no antibody as control. The 36 kDa band in the Myc-Tag immunoprecipitation shows 
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that the Myc-Tag antibody can immunoprecipitate the Ardl-Myc-His protein from TnT 
35S-labeled Ardl-Myc-His lysates. 
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Figure 3. 1 Specificity ofTubedown Antibodies. Ard1-Myc-His were prepared from TnT 
lysates of two different pcDNA3.1/Neo/Myc-His constructs containing either Tubedown or 
Ardl coding nucleotide sequences. TnT 35S-labeled Tubedown-Myc-His was 
immunoprecipitated with Narg1 (Narg1 IP), LE C10-20 (LE Cl0-20 IP), and Myc-Tag (Myc 
IP) antibodies, and no antibody (No Ab IP) as control. Immunoprecipitations were analyzed 
by SDS-PAGE and by reading photon emissions from a phosphor screen after 1 week of 
exposure to radioactive gels. TnT 35S-labeled Tubedown-Myc-His and Ard1-Myc-His lysates 
were used for comparison (Tubedown TnT and Ardl TnT lanes, respectively). 35S-labeled 
Ard1-Myc-His was immunoprecifsitated using the Myc-Tag antibody (Myc IP) and no 
antibody (No Ab IP) as control. 58-labeled Tubedown-Myc-His and 35S-labeled Ard1-Myc-
His are indicated with arrows at 108 kDa and 36 kDa, respectively. Photon emission bands at 
108 kDa in Narg1 and LE C10-20 immunoprecipitations proves that these antibodies 
recognize Tubedown (Experiments completed = 1 ). 
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3.2 Analysis of Tubedown/Dynamin Interaction 
To verify that endothelial cells express Dynamin, western blot analyses on whole 
celllysates (WCL) from RF/6A retinal endothelial cells were performed with Dynamin 
antibody [Fig. 3.2, WCL lanes]. Western blot analysis with Dynamin shows a band at 
1 00 k.Da confirming endothelial cells express Dynamin. 
To determine ifTubedown and Dynamin interact together, immunoprecipitations 
were prepared using LE CI0-20 (Tubedown) antibody followed by western blot analyses 
with Dynamin (Fig. 3.2, bottom panel) and Nargl (Tubedown) antibodies (Fig. 3.2, top 
panel) from RF/6A endothelial cell extracts [Fig. 3.2]. A double immunoprecipitation 
was performed followed by two separate western blot analyses because both Dynamin 
and Tubedown are 100 kDa. Control immunoprecipitations were prepared with rabbit 
pre-immune serum. Immunoprecipitations ofTubedown followed by Dynamin western 
blot analyses showed no band in the migration area ofDynamin (100 k.Da) suggesting 
that Tubedown and the Dynamin-2 endothelial isoform do not interact within RF /6A 
endothelial cells [Fig. 3.2]. 
Other combinations of immunoprecipitations followed by western blot analyses 
were performed using the Nargl antibody (Tubedown) for immunoprecipitation, and a 
second endothelial cell line (IEM) to further detect possible Tubedown and Dynamin 
interactions (results not shown). Immunoprecipitation using Dynamin antibody could not 
be performed because the antibody was not suitable for immunoprecipitations. Tubedown 
interaction with Dynamin was not observed following any of the immunoprecipitations I 
western blot analyses tested. 
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Figure 3. 2 Dynamin and Tubedown: Western Blot Analyses ofTubedown 
Immunoprecipitation. Immunoprecipitations (IP) prepared from RF /6A 
endothelial cell extracts using LE C10-20 (Tubedown IP) antibody or pre-immune 
rabbit serum (Pre-Immune IP) as control were analyzed by western blotting for 
Tubedown or Dynamin. Lanes with 5 J.!g and 10 J.!g of whole cell lysate (WCL) 
were used for protein amount comparison. Western blot analyses were conducted 
using Narg1 (Tubedown) antibody and Dynamin antibody (top and bottom panel, 
respectively). Tubedown and Dynamin are both at 100 kDa as indicated by 
arrows. An empty lane (blank) was left in between immunoprecipitations and 
WCL lanes to detect possible run-over of lanes when loading gel. Dynamin does 
not co-immunoprecipitate with Tubedown suggesting no interaction between 
Dynamin and Tubedown. Representative results are shown (Experiments 
completed = 5). 
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3.3 Analysis of Tubedown/AF -6 Interaction 
To verify that AF-6 is expressed in endothelial cells, western blot analyses of 
WCL from IEM cells were performed using AF-6 antibody (Fig. 3.3, WCL lanes). 
Western blot analysis with AF -6 shows a band at 200 kDa confirming endothelial cells 
express AF -6. 
To determine if Tubedown binds to AF -6, immunoprecipitations were performed 
with AF -6 antibody from IEM cell extracts followed by western blot analyses with AF -6 
(Fig. 3.3, bottom panel) or Nargl (Tubedown) antibodies (Fig. 3.3, top panel) [Fig. 3.3]. 
Immunoprecipitations with IgG1 negative control antibody were used as a control. AF -6 
western blot analyses ofNargl (Tubedown) immunoprecipitation showed no band in the 
migration area of AF -6 (200 kDa) suggesting that Tubedown and AF -6 do not bind 
within IEM cells [Fig. 3.3]. 
Other immunoprecipitations were performed with RT Cl0-20 (Tubedown) 
antibody. In addition, reciprocal experiments were performed using the AF -6 antibody. 
All immunoprecipitations were followed by western blot analyses with AF-6 and Nargl 
(Tubedown) (results not shown). Tubedown and AF-6 interactions were not detected 
with any immunoprecipitations/western blot analyses. 
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Figure 3. 3 AF-6 and Tubedown: Western Blot Analyses ofTubedown 
Immunoprecipitation. Immunoprecipitations (IP) prepared from IEM cell 
extracts using Narg1 (Tubedown IP) antibody and lgG1 negative control (lgG 1 IP) 
antibody were analyzed by western blot analysis for Tubedown or AF -6. Lanes 
with 25 J.!g and 50 J.!g of whole celllysates (WCL) were used for protein amount 
comparison. Western blot analyses were conducted using N arg 1 antibody 
(Tubedown) and AF-6 antibody (top and bottom panels, respectively). Tubedown 
and AF -6 are indicated with arrows at 100 kDa and 200 kDa, respectively. An 
empty lane (blank) was left in between immunoprecipitations and WCL lanes to 
detect possible run-over of lanes when loading gel. Lack of AF -6 in Tubedown 
immunoprecipitation suggests no interaction between AF -6 and Tubedown. 
Representative results are shown (Experiments completed = 3). 
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3.4 Analysis of Tubedown/Y 421-Phospho-Cortactin Interaction 
To verify that the levels of Y 4 21-Phospho-Cortactin are high enough to be 
detected in endothelial cells, western blot analyses on WCL of IEM cells were performed 
using the Y421-Phospho-Cortactin antibody [Fig. 3.4 & 3.5, WCL lanes]. Western blot 
analysis with Y421-Phospho-Cortactin shows a band at 100 kDa confirming endothelial 
cells express Y 4 21-Phospho-Cortactin. 
To determine if immunoprecipitation manipulations allowed for detection of 
Y421-Phospho-Cortactin by western blot analysis, immunoprecipitations and western 
analyses were completed in IEM cell extracts. Immunoprecipitation of Cortactin using 
4Fll antibody followed by western blot analyses with Y421-Phospho-Cortactin antibody 
(Fig. 3.4, top panel) and Cortactin (4Fll) antibody (Fig. 3.4, bottom panel) were 
conducted [Fig. 3.4]. Western blot analyses were first conducted with Y421-Phospho-
Cortactin antibody (Fig. 3.4, middle panel) and the membrane was then stripped andre-
probed with Cortactin 4Fll antibody (Fig. 3.4, bottom panel). Immunoprecipitation with 
lgGt negative control antibody was used as control. An 80 kDa band corresponding to 
the molecular weight of Cortactin was detected in the immunoprecipitation of Cortactin 
followed by western blot analysis with Y421-Phospho-Cortactin, verifying that 
immunoprecipitation manipulations allowed the detection of Y 421-Phospho-Cortactin 
within IEM cells [Fig. 3.4]. 
To determine ifTubedown and Y421-Phospho-Cortactin interact together, 
immunoprecipitation of Tubedown was performed followed by western blot analyses of 
Y 421-Phospho-Cortactin, Cortactin, and Tubedown within IEM cell extracts. A triple 
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immunoprecipitation ofNarg1 (Tubedown) was performed and three separate western 
blot analyses were conducted. Western blot analyses were completed with Y 421-
Phospho-Cortactin antibody (Fig. 3.5, middle panel), Cortactin 4F11 antibody (Fig. 3.5, 
bottom panel), and Narg1 (Tubedown) antibody (Fig. 3.5, top panel) [Fig. 3.5]. Cortactin 
western blots (Fig. 3.5, bottom panel) were stripped and reprobed with Narg1 
(Tubedown) antibody (Fig. 3.5, top panel) to confirm the presence ofTubedown. 
Immunoprecipitation with IgG1 negative control antibody was used as control. 
Immunoprecipitation of Tubedown followed by Cortactin western blot analyses showed 
the binding between Cortactin and Tubedown. However, immunoprecipitation of 
Tubedown followed by Y421-Phospho-Cortactin western analyses shows no band. These 
results suggest the interaction between Tubedown and Cortactin does not occur in IEM 
cells when Cortactin is phosphorylated at Y421 [Fig. 3.5]. 
Immunoprecipitations were also carried out using LE C10-20 (Tubedown) and RT 
C 10-20 (Tubedown) antibodies followed by western analyses for both with Y 421-
Phospho-Cortactin and Nargl (Tubedown) antibodies (results not shown). 
Immunoprecipitation ofNarg1 (Tubedown) antibody with double antibody and double 
protein concentrations were also completed to detect minimal amounts of Y 421-Phospho-
Cortactin interaction with Tubedown. Western blot analyses were also conducted on 
WCL ofRF/6A endothelial cells with Y421-Phospho-Cortactin antibody verifying Y421-
Phospho-Cortactin can be detected in retinal-choroidal endothelial cells (results not 
shown). Immunoprecipitations with Y 421-Phospho-Cortactin antibody could not be 
performed because antibody is not suitable for immunoprecipitations. Tubedown and 
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Y 4 21 -Phospho-Cortactin binding could not be detected in any of the 
immunoprecipitation I western blot analyses performed. 
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Figure 3. 4 Y421-Phospho-Cortactin and Cortactin: Western Blot Analyses of 
Cortactin Immunoprecipitation. Immunoprecipitations (IP) were prepared from 
IEM cell extracts using Cortactin (Cortactin IP) and IgG1 negative control (IgG1 IP) 
antibodies. Immunoprecipitations were analyzed by western blotting using Y 421-
Phospho-Cortactin antibody and Cortactin antibody (top and bottom panels, 
respectively). Arrows at 80 kDa indicate Y 421-Phospho-Cortactin and Cortactin. 
Lanes with 35 f.lg and 50 f.lg of whole celllysates (WCL) were used for protein 
amount comparison. An empty lane (blank) was left in between immunoprecipitations 
and WCL lanes to detect possible run-over of lanes when loading gel. Western blot 
analyses verify Y421-Phospho-Cortactin can be detected with Cortactin 
immunoprecipitation (Experiments completed = 1 ). 
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Figure 3. 5 Y421-Phospho-Cortactin, Cortactin, and Tubedown: Western Blot 
Anaylses of Tubed own Immunoprecipitation. Immunoprecipitations (IP) were 
prepared from IEM cell extracts using N arg 1 (Tubedown IP) antibody and lgG 1 
negative control (lgG 1 IP) antibody. Immunoprecipitations were analyzed by 
western blot analyses using Y421-Phospho-Cortactin antibody, Narg1 (Tubedown) 
antibody, and Cortactin antibody (top, middle, and bottom panels, respectively). 
Arrows at 80 kDa indicate Y421-Phospho-Cortactin and Cortactin. Tubedown is 
indicated by an arrow at 100 kDa. Lanes with 35 J.lg and 50 J.lg ofWCL were used 
for protein amount comparison. An empty lane (blank) was left in-between 
immunoprecipitations and WCL to detect possible run-over of lanes when loading 
gel. Western blot analyses show further evidence of Tubedown and Cortactin' s 
interaction, but suggest no interaction between Tubedown and Y 421-Phospho-
Cortactin. Representative results are shown (Experiments completed = 1 0). 
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3.5 Analysis of Tubedown/c-Src Interaction 
To verify that endothelial cells express c-Src, western blot analyses on WCL from 
IEM and RF/6A endothelial cells were performed with c-Src antibody [Fig. 3.6 and 3.7, 
WCL lanes]. Western blot analyses with c-Src antibody showed a band at 60 kDa 
confirming endothelial cells express c-Src. 
To determine if Tubedown and c-Src interact together, Tubedown 
immunoprecipitations were prepared using LE Cl0-20 (Tubedown) antibody, MI-C755 
(Tubedown) antibody, and Nargl (Tubedown) antibody [Fig. 3.6]. Immunoprecipitations 
with no antibody were used as control. To test that the Nargl antibody, which is 
stabilized by adding bovine serum albumin (BSA), would not cause an artificial band to 
appear within c-Src molecular weight (60 kDa) the Nargl antibody alone was tested. 
Western blot analyses were conducted with Nargl (Tubedown) antibody and c-Src 
antibody (top and bottom panels, respectively). Due to use of secondary anti-mouse 
antibody for western blot procedure, antibodies from immunoprecipitations and possibly 
BSA from Nargl antibody preparation were detected during c-Src western blot analyses. 
Two bands present in the WCL lane with c-Src western blot analysis were sometimes 
observed [Fig. 3.6]. This is possibly due to degredation of the protein from cell extract. 
Tubedown immunoprecipitations followed by c-Src western blot analyses showed no 
band in the migration area of c-Src (60 kDa) suggesting that Tubedown and Src do not 
interact within RF/6A endothelial cells [Fig. 3.6]. 
To further validate Tubedown and c-Src do not interact immunoprecipitations 
were also completed with c-Src antibody from RF /6A endothelial cell extracts [Fig. 3. 7]. 
45 
Western blot analyses of immunoprecipitations were conducted with MI -C7 55 
(Tubedown) (Fig. 3.7, top panel), Nargl (Tubedown) (Fig. 3.7, middle panel), and c-Src 
(Fig. 3. 7, bottom panel) antibodies. Immunoprecipitations with no antibody were used as 
control. Immunoprecipitations of c-Src followed by Tubedown western blot analyses 
showed no band in the migration area ofTubedown (100 kDa) suggesting that Tubedown 
and c-Src do not interact within endothelial cells [Fig. 3. 7]. 
To confirm antibodies were not interfering with a possible Tubedown and c-Src 
regions of interaction, stable RF/6A clones harboring pcDNA3.1/Neo/Myc-His constructs 
containing either Tubedown (RF/6A-Tubedown-Myc-His) or Ardl (RF/6A-Ardl-Myc-
His) coding sequences were used to study the interaction between Tubedown, Ard 1 and 
c-Src. Immunoprecipitations ofTubedown and Ard1 were prepared using Myc-Tag 
antibodies from either RF/6A-Tubedown-Myc-His or RF/6A-Ard1-Myc-His, respectively 
[Fig. 3.8]. Control immunoprecipitations were completed with c-Src antibody and Myc-
Tag antibody from RF/6A parental endothelial cells. Western blot analyses were 
completed with Narg1 (Tubedown) antibody, c-Src antibody, and Myc-Tag antibody for 
Ard1 detection. Narg1 (Tubedown) western blot analysis showed bands for both 
Tubedown-Myc-His and endogenous Tubedown (108 k.Da and 100 kDa, respectively). 
Immunoprecipitations prepared with the Myc-Tag antibody from RF/6A-Ard1-Myc-His 
clones detected the interaction between Ard1 and endogenous Tubedown. However, no 
interactions could be detected between Tubedown and c-Src or Ard1 and c-Src because 
heavy and light chains of the Myc-Tag antibody left bands in the migration area of c-Src 
(60 kDa). 
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Since irnmunoprecipitations from endogenous lystates could not be completed 
with the Myc-Tag antibody to detect an interaction between Tubedown and c-Src, in vitro 
irnmunoprecipitations with Myc-Tag antibody were prepared from 35S-labeled 
Tubedown-Myc-His or 35S-labeled Ardl-Myc-His TnT lysates. To test that neither 
Tubedown nor Ardl interact with c-Src, purified c-Src (Lydon et al., 1992) was incubated 
with 35S-labeled Tubedown-Myc-His or 35S-labeled Ardl-Myc-His TnT lysates to test 
their binding affinity [Fig. 3.9]. Irnmunoprecipitations ofTubedown or Ardl were 
prepared with Myc-Tag antibody from 35S-labeled Tubedown-Myc-His or 35S-labeled 
Ardl-Myc-His lysates generated from TnT. Irnmunoprecipitation with no antibody from 
35S-labeled Tubedown-Myc-His or 35S-labeled Ardl-Myc-His TnT lysates were used as 
control. Each irnmunoprecipitation was incubated with 550 ng of purified c-Src. For 
protein amount comparisons 200 ng of purified c-Src and one tenth of the TnT lysates of 
35S-labeled Tubedown-Myc-His or 35S-labeled Ardl-Myc-His used for 
immunoprecipitations were loaded. Detection of photon emissions from radioactively 
labeled TnT lysates was completed to test ifTubedown and Ardl were present in control 
and irnmunoprecipitation lanes [Fig. 3.9, Tbdn TnT Lysates, Myc IP (Tbdn TnT Lysates), 
Ardl TnT Lysates, and Myc IP (Ardl TnT Lysates) lanes, respectively]. Western blot 
analyses were carried out with c-Src antibody for c-Src protein detection [Fig. 3.9]. No 
c-Src was detected with immunoprecipitation of 35S-labeled Tubedown-Myc-His or 35S-
labeled Ardl-Myc-His incubated with purified c-Src, suggesting neither Tubedown nor 
Ardl are directly interacting with c-Src. This supports the result using cell extracts 
presented above. 
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Other combinations of immunoprecipitations followed by western blot analyses 
were performed using double concentrations of the LE C 10-20 (Tubedown) antibody and 
double the amount of protein (results not shown). Tubedown and c-Src interactions could 
not be detected in any of the in vitro experiments performed. 
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Figure 3. 6 Tubedown and c-Src: Western Blot Analyses ofTubedown 
Immunoprecipitation. Immunoprecipitations (IP) were prepared from IEM cell 
extracts. Tubedown immunoprecipitations were prepared using LE Cl0-20 antibody, 
MI-C755 antibody, and Narg1 antibody. No antibody (No Ab IP) 
immunoprecipitation was used as control. Immunoprecipitations were analyzed by 
western blot analyses using Narg1 (Tubedown) antibody and c-Src antibody 
antibodies (top and bottom panels, respectively). Arrows at 100 kDa and 60 kDa 
indicate Tubedown and c-Src, respectively. An arrow above 60 kDa possibly 
represents BSA that the Narg1 antibody was stabilized with. An arrow below 60 kDa 
represents heavy chains of antibodies (Ab) from immunoprecipitations. A lane with 
50 J.lg ofWCL was used for protein amount comparison. An empty lane (blank) was 
left in-between immunoprecipitations and WCL to detect possible run-over of lanes 
when loading gel. C-Src is not co-immunoprecipitating with Tubedown, suggesting 
Tubedown and c-Src do not interact (Experiments completed = 1 ). 
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Figure 3. 7 Tubedown and c-Src: Western Blot Analyses of c-Src 
Immunopreciptiation. Immunoprecipitations (IP) were prepared from RF /6A 
endothelial cell extracts using c-Src ( c-Src IP) antibody or no antibody (No Ab IP) 
control. Immunoprecipitations were analyzed by western blot analyses using MI-
C755 (Tubedown) antibody, Narg1 (Tubedown) antibody and c-Src antibody (top, 
middle, and bottom panels, respectively). Arrows at 100 kDa and 60 kDa indicate 
Tubedown and c-Src, respectively. A lane with 50 ~g ofWCL was used for 
protein amount comparison. An empty lane (blank) was left in-between 
immunoprecipitations and WCL to detect possible run-over of lanes when loading 
gel. Tubedown is not co-immunoprecipitating with c-Src, suggesting Tubedown 
and c-Src do not interact. Representative results are shown (Experiments 
completed = 2). 
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Figure 3. 8 Tubedown and c-Src: Western Blot Analyses of c-Src and Myc-Tag 
Immunoprecipitations. Immunoprecipitations (IP) were prepared from parental 
RF /6A endothelial cell extracts using c-Src ( c-Src IP) antibody or Myc-Tag antibody 
(Myc IP) for controls. Immunoprecipitations were also prepared using Myc-Tag 
antibody from RF/6A Tbdn-Myc-His or Ard1-Myc-His RF/6A cell clones lysates to 
immunoprecipitate Tubedown and Ard 1, respectively. Immunoprecipitations were 
analyzed by western blotting using Narg1 (Tubedown) antibody, c-Src antibody, and 
Myc-Tag antibody for Ard1 detection (top, middle, and bottom panels, respectively). 
Arrows at 108 kDa, 100 kDa, 60 kDa, and 36 kDa indicate Tubedown-Myc-His, 
Tubedown, c-Src, and Ard1-Myc-His, respectively. An arrow below 60 kDa 
represents heavy chains of antibodies (Ab) from immunoprecipitations. These results 
further prove the interaction between Tubedown and Ard1. However, no interaction 
between Tubedown and c-Src could be detected because heavy and light chains of 
antibody are in the migration area of c-Src (60 kDa). Representative results are shown 
(Experiments completed = 2). 
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Figure 3. 9 Tubed own, c-8rc, and Ardl: Photon Emissions and Western Blot Analysis of 
358-Tubedown-Myc-His and 358-Ardl-Myc-His Immunoprec~itations Incubated with 
Purified c-8rc. Immunoprecipitations (IP) were prepared from 3 S-labeled Tubedown-Myc-His 
(Tbdn TnT Lysate) and 35S-labeled Ardl-Myc-His (Ardl TnT Lysate) TnT lysates. 35S-labeled 
Tubedown-Myc-His was immunoprecipitated with Myc-Tag (Myc IP) antibody and no antibody 
(No Ab IP) as control. 35S-labeled Ard1-Myc-His was also immunoprecipitated with Myc-Tag 
(Myc IP) antibody and no antibody (No Ab IP) as control. All immunoprecipitations were 
incubated with purified c-Src. Purified c-Src ( c-Src ), 35S-labeled Tubedown-Myc-His (Tbdn 
TnT Lysate), and 35S-labeled Ardl-Myc-His (Ard1 TnT Lysate) were loaded as controls. 
Immunoprecipitations were analyzed by western blot analyses using c-Src antibody for c-Src 
protein detection (middle panel). 35S-labeled Tubedown-Myc-His and 35S-labeled Ard1-Myc-
His were analyzed by reading photon emissions from a phosphor screen after 1 week of exposure 
(top and bottom panels, respectively). Arrows at 108 kDa, 60 kDa, and 36 kDa indicate 35S-
labeled Tubedown-Myc-His, c-Src, and 35S-labeled Ardl-Myc-His, respectively. Heavy chains 
of Myc-Tag antibody from immunoprecipitations are indicated with an arrow under 60 kDa 
arrow. An empty lane (blank) was left in-between immunoprecipitations and controls to detect 
possible run-over of lanes when loading gel. No direct interaction between Tubedown nor Ard1 
with c-Src could be detected (Experiments completed = 1). 
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3.6 Analysis of Tubedown/Z0-1 Interaction 
To verify Z0-1 could be detected in endothelial cells, western blot analyses of 
WCL from RF/6A endothelial cells were conducted [Fig. 3.10, WCL lane] . Western blot 
analysis with Z0-1 antibody shows a band at 225 kDa confirming endothelial cells 
express Z0-1. 
To determine if Z0-1 and Tubedown interact together, immunoprecipitations 
were prepared using Z0-1 (R40.76) antibody and no antibody as control with RF/6A 
endothelial cell extracts. Immunoprecipitations were analyzed by western blot using Z0-
1 (R40.76) (Fig. 3.10, bottom panel) and Narg1 (Tubedown) antibodies (Fig. 3.10, top 
panel) [Fig. 3.1 0]. No band was observed around Tubedown' s molecular weight (1 00 
kDa) in immunoprecipitations of Z0-1 followed by western blot analyses with antibodies 
for Tubedown, suggesting that Z0-1 and Tubedown do not form a complex within RF/6A 
endothelial cells. 
Immunoprecipitations were also carried out using Z0-1 (1A12) antibody followed 
by western blot analyses with Z0-1 (R40. 76) antibody and Narg1 (Tubedown) antibody 
to further detect possible Tubedown and Z0-1 interactions (results not shown). No 
detection of Tubedown and Z0-1 binding could be detected by immunoprecipitations 
followed by western blot analyses. 
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Testing potential Z0-1 redistribution in Tubedown knockdowns to elucidate 
Tubedown 's role in the regulation of ocular endothelial permeability. 
3.7 Analysis of Z0-1 Distribution in Tubedown Knockdowns 
To determine ifTubedown suppression affects Z0-1 expression and distribution 
within the cell, transient knockdowns ofTubedown were performed in RF/6A endothelial 
cells. Transient Tubedown knockdowns were prepared by electroporation of 10-20 nM 
Tubedown siRNA. Co-transfection of green fluorescent protein (GFP) was used to 
monitor transfection efficiency. Transient transfection controls were 10-20 nM control 
siRNA with GFP, GFP only, and non-transfected. The different transfections were 
conducted in 3 separate experiments. Transfection efficiencies of GFP expressions were 
calculated for each experiment [Fig. 3.11]. Figure 3.11 shows all samples were efficiently 
transfected to a similar percentage ( 40-5 Oo/o). 
Western blot analyses using Narg1 (Tubedown) antibody (Fig. 3.12, top panel) 
and Tubulin antibody (Fig. 3.12, bottom panel) were completed on WCL oftransfected 
cells to detect percentage ofTubedown suppressed [Fig. 3.12]. Densitometric analyses 
were completed on western blots of Tubedown and Tubulin from separate transfection 
experiments revealing a ,...,90% decrease in Tubedown expression when compared to GFP 
only transfected cells (p < 0.05, ANOV A) [Fig. 3.13] (Paradis et al, 2002; 2008). 
To determine ifTubedown suppression affects Z0-1 expression, western blot 
analyses were conducted with Z0-1 (R40.76) antibody on WCL from transient and stable 
knockdowns ofTubedown [Fig. 3.14]. WCL from RF/6A endothelial cells transiently 
transfected with 20 nM Tubedown siRNA or control siRNA were used for Z0-1 protein 
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concentration analysis because 20 nM Tubedown siRNA had a slightly higher efficiency 
to knockdown Tubedown expression 72 hours post transfection [Fig. 3.14]. Western blot 
analyses with Tubulin antibody were used as loading control. Densitometric analyses 
were completed on triplicate western blots of Z0-1 and Tubulin from separate 
transfection experiments, which show no significant changes in Z0-1 level of expression 
in correlation with Tubedown suppression (p < 0.05, ANOVA) [Fig. 3.15, Fig. 3.16]. 
To detect if suppression of Tubedown affects Z0-1 distribution within a cell 
transient knockdowns ofTubedown were fluorescently stained with Z0-1 (R40.76) 
antibody followed by rhodamine red anti-mouse antibody. A stable knockdown clone of 
Tubedown was used as a positive control for comparison to transient assays. Cells were 
mounted with medium containing DAPI to view nucleus of cell [Fig. 3.17]. Quantitation 
of Z0-1 at the cell perimeter revealed a ,....,50 % decreased in Z0-1 perimeter expression in 
a stable knockdown ofTubedown (ASTB#20). Additionally, a ,....,40% decreased in Z0-1 
perimeter expression in control siRNA transfected cells when compared to parental 
RF/6A (p < 0.05, ANOVA) [Fig. 3.18]. 
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Figure 3. 10 Z0-1 and Tubedown: Western Blot Analyses of Z0-1 
Immunoprecipitation. Immunoprecipitations (IP) were preformed from 
RF /6A endothelial cell extracts using Z0-1 antibody (Z0-1 IP) or no 
antibody (No Ab) control. 15J.!g ofWCL was used for protein amount 
comparison. Western blot analyses of immunoprecipitations were completed 
using Z0-1 antibody and Narg1 (Tubedown) antibody. Tubedown and Z0-1 
are indicated with arrows at 100 kDa and 225 kDa, respectively. An empty 
lane (blank) was left in between immunoprecipitations and WCL lanes to 
detect possible run-over of lanes when loading gel. Tubedown is not co-
immunoprecipitating with Z0-1 suggesting no interaction between the Z0-1 
and Tubedown. Representative results are shown (Experiments completed = 
3). 
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Figure 3. 11 G FP Transfection Efficiencies in Transiently Transfected RF /6A 
Endothelial Cells. To determine the efficiencies of transient transfections, GFP 
expression was quantitated through cell count. The chart represents the average 
transfection efficiency of the 3 experiments with error bars representing +I- standard error 
(SEM) (p < 0.05, ANOV A). Bars represent the percentage of cells that expressed GFP 
over total number of cells within a 20 mm x 20 mm field (Experiments completed = 3). 
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Figure 3. 12 Tubedown and Tubulin: Western Blot Analyses ofWCL from 
Transient Tubedown Knockdowns. Western blot analyses were performed on 75 J.lg 
WCL from triplicate transient transfections of RF /6A endothelial cells. RF /6A 
endothelial cells were transfected with 10 or 20 nM Tubedown siRNA and GFP (Tbdn 
siRNA + GFP), 10 or 20 nM control siRNA and GFP (Ctrl siRNA + GFP), and GFP 
alone (No siRNA + GFP). Western blot analyses were conducted using Nargl 
(Tubedown) antibody and Tubulin antibody. Tubedown and Tubulin are indicated with 
arrows at 100 kDa and 55-58 kDa, respectively. Representative results are shown 
(Experiments completed= 3). 
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Figure 3. 13 Quantitative Analysis: Tubedown Expression in Transient Tubedown 
Knockdowns. Densitometric analyses were completed on Tubedown and Tubulin 
western blots of WCL from triplicate transfections of RF /6A endothelial cells for which a 
representative is shown in Figure 3.12. RF/6A endothelial cells were transiently 
transfected with 10 or 20 nM control siRNA with GFP (Ctrl siRNA + GFP), 10 or 20 nM 
Tubedown siRNA with GFP (Tbdn siRNA + GFP), and GFP alone (No siRNA + GFP). 
The histogram represents the averages of each of the 3 transfections. Bars represent 
densitometric analyses of Tubedown over Tubulin band intensities with error bars 
representing +/- SEM. Significant differences are designated with * (p < 0.05, ANOV A). 
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Figure 3. 14 Z0-1 and Tubulin: Western Blot Analyses ofWCL from Stable and 
Transient Tubedown Knockdowns. Western blot analyses were performed on 70 J..Lg 
WCL from stable and transient knockdowns of Tubedown in RF /6A endothelial cells. 
RF/6A endothelial cells were transfected with 20 nM Tubedown siRNA and GFP (Tbdn 
siRNA + GFP), 20 nM control siRNA and GFP (Ctrl siRNA + GFP), and GFP alone (No 
siRNA + GFP). ASTB clone 20 (ASTB#20) was used to detect Z0-1 expression in a 
stable knockdown of Tubedown. Parental RF /6A endothelial cells without transfection 
were used for protein amount comparison. Western blot analyses were conducted using 
Z0-1 and Tubulin antibodies (top and bottom panels, respectively). Tubulin and Z0-1 are 
indicated with arrows at 55-58 kDa and 225 kDa, respectively. Representative results are 
shown (Experiments completed = 3 ). 
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Figure 3. 15 Quantitative Analysis: Z0-1 Expression in Transient Tubedown 
Knockdowns. Densitometric analyses were completed on Z0-1 and Tubulin western 
blots of WCL from triplicate transfections of RF /6A endothelial cells. RF /6A endothelial 
cells were transfected with 20 nM control siRNA with GFP (Ctrl siRNA + GFP), 20 nM 
Tubedown siRNA with GFP (Tbdn siRNA + GFP), and GFP alone(+ GFP) (Left 
histogram). Transiently transfected cells were compared to cells transfected with GFP 
alone. The histogram represents the averages of triplicate experiments. Bars represent 
densitometric analyses of Z0-1 over Tubulin band intensities with error bars representing 
+/- SEM for each sample (p < 0.05, ANOVA). No significant difference in Z0-1 
expression was detected within transiently transfected RF/6A endothelial cells when 
compared to GFP transient knockdowns ofTubedown. 
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Figure 3. 16 Quantitative Analysis: Z0 -1 Expression in a Stable Tubedown 
Knockdown Clone. Densitometric analyses were completed on Z0-1 and Tubulin 
western blots of WCL from triplicate transfections of RF /6A endothelial cells. RF /6A 
endothelial cells were transfected with 20 nM control siRNA with GFP (Ctrl siRNA + 
GFP), 20 nM Tubedown siRNA with GFP (Tbdn siRNA + GFP), and GFP alone(+ GFP) 
(Left histogram). Transiently transfected cells were compared to cells transfected with 
GFP alone. The histogram represents the averages of triplicate experiments. Bars 
represent densitometric analyses of Z0-1 over Tubulin band intensities with error bars 
representing +/- SEM for each sample (p < 0.05, ANOV A). No significant difference in 
Z0-1 expression was detected within transiently transfected RF /6A endothelial cells 
when compared to GFP transient knockdowns ofTubedown. 
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Figure 3. 17 Fluroescent Staining: Z0-1 Distribution in Stable and Transient 
Tubedown Knockdowns. Fluorescent microscopy analyses on transient or stable 
knockdowns and corresponding controls are stained for Z0-1 (red) expression pattern. 
Z0-1 expression distribution is shown in parental RF/6A endothelial cells (A) and a 
stable Tubedown knockdown clone, ASTB#20 (B). Z0-1 expression distributrion is 
also shown in RF/6A endothelial cells transiently transfected with GFP alone (C), 20 
nM Tubedown siRNA and GFP (D), or 20 nM control siRNA and GFP (E). RF/6A 
endothelial cells were also stained using the lgG1 negative control antibody for 
comparison (F). All images are a merge ofZ0-1 (red) staining and nuclear staining 
with DAPI (blue). Images shown were taken at 40 X magnification with a 110 JlSec 
exposure. Arrows show Z0-1 perimeter expression. Representative images are 
shown (experiments completed = 3 ). 
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Figure 3. 18 Z0-1 Cell Perimeter Quantitation of Stable and Transient 
Knockdowns of Tubed own. Fluorescent microscopy analyses on transient and 
stable knockdowns of Tubedown stained with Z0-1 were quantitated. RF /6A 
endothelial cells were transiently transfected with 20 nM Tubedown siRNA and GFP 
(Tbdn siRNA), 20 nM control siRNA (Ctrl siRNA), and GFP alone (No siRNA). 
Stable knockdown of Tubedown is represented with Tubedown knockdown clone 20 
(ASTB#20). Parental RF /6A endothelial cells are used for control (Parental). 
Quantitation was conducted by counting cells that expressed Z0-1 at the perimeter of 
the cell where paracellular permeability is regulated. Bars represent the average of 
three transfections with a minimum of 100 cells counted per bar. Error bars represent 
+I- SEM of samples. Significant differences are designated with* (p < 0.05, 
ANOV A). Z0-1 perimeter expression is notably decreased in stable knockdowns 
when compared to parental controls. However, when comparing Tubedown siRNA 
to control siRNA transfected RF /6A endothelial cells there is a significant difference 
in Z0-1 perimeter expression. In contrast, comparing Tubedown siRNA to cells only 
transfected with GFP showed no difference in Z0-1 perimeter expression. 
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4.0 DISCUSSION 
Wet AMD, PDR, and ROP result from abnormal vessel growth within the eye and 
together they represent the leading causes of blindness in the industrialized world 
(Konerding, 2004; Sato, 2010). In 2008 there were approximately 50 million blind 
individuals and three times that amount with some degree of vision loss (Woldeyes and 
Adamu, 2008). Currently, treatments for neovascular retinopathies are insufficient at 
eradicating the neovascular progression, do not address the underlying cause of the 
disease, and cannot adequately repair the resulting damage to the retina (Day et al., 2011 ; 
Horster et al. , 2011 ; Kinnunen and Yla-Herttuala, 2012). Defining the mechanisms 
leading to abnormal neovascularization of eye is a critical step to develop new therapies 
for neovascular retinopathies. 
Drs. Gendron and Paradis' laboratory have identified the Tubedown protein as a 
key regulator of ocular angiogenesis through regulation of permeability specifically 
within the retinal-choroidal endothelium (Gendron et al. , 2001; Wallet al. , 2004; Paradis 
et al. , 2008; Dr. H. Paradis [Memorial University ofNewfoundland], personal 
communication). Furthermore, they have observed a decrease in Tubedown expression 
in wet AMD, PDR, and ROP correlating to areas ofneovascularization seen in patients 
(Gendron et al. , 2001 ; Gendron et al., 2006; Gendron et al., 2010). Mechanistic 
investigation to determine how Tubedown regulates the retinal-choroidal endothelial 
permeability pathways could identify a new target for anti -angiogenic therapeutics, and 
possibly reveal the underlying pathophysiological cause of neovascular retinopathies. To 
elucidate Tubedown' s involvement in the regulation of permeability, I explored binding 
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partners for Tubedown with other known protein regulators of the permeability pathways. 
Investigation of Tubedown interactions with Dynamin, AF -6, Y 421-Phospho-Cortactin, 
c-Src, and Z0-1 were conducted. In addition, I hypothesized that Tubedown may 
regulate the distribution of Z0-1, a key component of paracellular permeability within 
endothelial cells. 
Dynamin is a known regulator of transcellular permeability. Immunodepletion of 
Dynamin-2 stops the cinching off of a vesicle at the cell perimeter during endocytosis, 
essentially abolishing transcytosis in endothelial cells (Cook et al. , 1996; Jones et al., 
1998). Since stable Tubedown knockdown clones show increased transcellular 
permeability (Paradis et al, 2008), I speculated that Tubedown might regulate 
transcellular permeability through an interaction with Dynamin-2. Immunoprecipitation 
in combination with western blot analyses indicated no interaction between Tubedown 
and Dynamin-2 within RF/6A or IEM endothelial cells [Fig. 3.2]. These results suggest 
that Tubedown is not regulating transcytosis through an interaction with Dynamin-2. 
Many studies have shown that AF -6 is a regulator of paracellular permeability 
(Mandai et al. , 1997; Yokoyama et al. , 2001). AF-6 is required for structural 
organization of both AJs and TJs in the paracellular permeability pathway (Ikeda et al. , 
1999; Zhadanov et al., 1999). Stable Tubedown knockdown clones show increased 
paracellular permeability (Dr. H. Paradis [Memorial University of Newfoundland], 
personal communication). In addition, immunoprecipitation of Tubedown in 
combination with mass spectrometry analysis from IEM cells showed ADIP to co-
immunoprecipitate with Tubedown, a known binding partner for AF -6 (Dr. H. Paradis 
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[Memorial University of Newfoundland], personal communication; Fukumoto et al. , 
2011 ). Therefore, I hypothesized that Tubedown may regulate paracytosis through an 
interaction with AF -6. Immunoprecipitation and western blot analyses indicated no 
interaction between Tubedown and AF-6 in IEM cells [Fig. 3.2]. These results suggest 
that Tubedown does not regulate paracytosis through an interaction with AF -6. 
Our lab has previously concluded that Tubedown interacts with the actin-binding 
protein Cortactin (Paradis et al., 2008). Cortactin is involved in the regulation of both 
transcellular and paracellular permeability through its interaction with the actin 
cytoskeleton (Dudek and Garcia, 2001 ; Osborn et al. , 2006; Zhu et al. , 2007). 
Tubedown' s interaction with Cortactin could be the mechanism by which Tubedown 
regulates paracellular and transcellular permeability in endothelial cells. Phosphorylation 
of Cortactin has been shown to increase its interaction with the transcellular permeability 
regulator Caveolin-1 and increase endocytosis overall (Cao et al. , 201 0). Moreover, 
multiple studies have shown that increased c-Src kinase activity leads to increased 
phosphorylation of Cortactin and enhanced transcytosis (Cao et al. , 201 0; Lambotin et al. , 
2005; Yang et al. , 2006). C-Src phosphorylation of Cortactin is progressive with Y 421 
being the initial site of tyrosine phosphorylation by c-Src (Huang et al. , 1998). I was 
interested to examine if Tubedown and Cortactin interact when Cortactin is 
phosphorylated at Y 421. Interestingly, no interaction with Tubedown and Y 421-
Phospho-Cortactin could be detected using immunoprecipitation and western blotting 
techniques with IEM cells [Fig. 3.4]. Tubedown and Y421-Phospho-Cortactin 
interactions were investigated in IEM cells because Y 421-Phospho-Cortactin has higher 
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expression levels when compared to RF /6A endothelial cells. As Y 421 is believed to be 
the first tyrosine site phosphorylated on Cortactin, this result suggests that Tubedown 
does not interact with Cortactin when Y 421 is phosphorylated. It is possible that 
Tubedown binds Cortactin and essentially prevents its tyrosine phosphorylation by either 
relocation or sequestration of Cortactin keeping it away from kinases like c-Src. 
Furthermore, Tubedown has been shown to interact with the acetyltransferase Ardl to 
mediate acetylation of other proteins (Gendron et al. , 2000; Arenesen et al. , 2002). In 
addition, decreased Tubedown expression leads to Ardl suppression (Paradis et al. , 
2008). Acetylation has been shown to affect levels of phosphorylation of proteins 
(Matsuzaki et al., 2005). Acetylation of Cortactin is known to decrease its interaction 
with actin and subsequently decrease cell migration (Zhang et al. , 2009). A second 
possibility is that Tubedown could regulate transcellular permeability through acetylation 
of Cortactin subsequently attenuating tyrosine phosphorylation and decreasing 
transcytosis. This hypothesis is further supported by a recent article by Meiler et al. 
confirming that acetylation of Cortactin is anatogonistic to c-Src tyrosine phosphorylation 
ofCortactin (Meiler et al., 2012). 
C-Src is known to act as a ' switch' in transcellular permeability regulation (Hu 
and Minshall, 2009). It has been shown to phosphorylate Dynamin, Caveolin-1 , and 
Cortactin, thereby increasing transcellular permeability (Tehrani et al. , 2007; Yang et al. , 
2006; Hu et al. , 2008). Previous work in the labratories of Drs. Paradis and Gendron had 
suggested that decreased Tubedown expression possiby correleates with an increase in 
Y416-Phospho-Src (Dr. H Paradis and N. Ho [Memorial University ofNewfoundland], 
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personal communication; Whelan, 2011 ). Therefore, I hypothesized that Tubedown may 
interact with c-Src; however, results showed no evidence that Tubedown co-
immunoprecipitates with c-Src [Fig. 3 .6, Fig. 3. 7, Fig 3 .8]. Further in vitro studies were 
also conducted to test if Tubedown and c-Src can directly bind. In vitro tests showed no 
direct interaction between Tubedown and c-Src [Fig. 3.9]. These results suggest that 
Tubedown is not regulating transcellular permeability through an interaction with c-Src 
within endothelial cells. 
Z0-1 has been shown to regulate paracellular permeability in several ways 
including recruitment of inter-endothelial junctions to the cell perimeter (Ikenouchi et al., 
2007; Yamamoto et al. , 1997; Umeda et al. , 2004; Ebnet et al. , 2000; Rimm et al., 1995). 
I hypothesized that Tubedown may regulate paracellular permeability through an 
interaction with Z0-1. No interaction between Z0-1 and Tubedown could be detected 
through immunoprecipitations and western blotting techniques in RF /6A endothelial cells 
[Fig. 3.1 0] . These results suggest that Tubedown does not regulate paracytosis through 
an interaction with Z0-1 . 
In addition, previous work in the Drs. Paradis and Gendron labratoratories had 
shown stable knockdown clones of Tubedown have decreased Z0-1 expression at the cell 
perimeter where Z0-1 regulates paracellular permeability (Dr. H. Paradis [Memorial 
University of Newfoundland], personal communication). The previous work had shown 
the stable Tubedown knockdown clones did not correlate with a change in Z0-1 overall 
expression in RF/6A endothelial cells (Dr. H. Paradis [Memorial University of 
Newfoundland], personal communication), so a change in cellular localization model was 
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proposed. To further investigate the hypothesis that Tubedown relocates Z0-1 to the cell 
perimeter a transient Tubedown knockdown protocol was generated. Transfection 
efficiencies of GFP showed average transfection efficiency ( 40-50 % ). However, siRNA 
induced knockdown of Tubedown showed a 90 % decrease in Tubedown expression 
suggesting a transfection efficiency of at least 90 % [Fig. 3.13]. The low GFP 
transfection efficiencies could be caused by the fact that GFP transfections were 
completed with super-coiled doubled stranded plasmid. However, transient Tubedown 
knockdowns were completed with siRNA's. Therefore, the methods oftransfection are 
different. 
Transient and stable knockdowns of Tubedown did not correlate with a change of 
expression for Z0-1 by western blotting techniques [Fig. 3.15, Fig. 3.16]. To test if 
Tubedown relocates Z0-1 to the cell perimeter, endothelial cells with stable and transient 
knockdowns ofTubedown were immunofluorescently stained for Z0-1. Oddly, control 
siRN A transfections showed a significant decrease of Z0-1 expression at the cell 
membrane when compared to Tubedown siRNA transfections. This could possibly be 
caused by other protein knockdowns. The control siRNA (SC47) was purchased in 2007, 
and at the time its sequence had no significant matches when analyzed with BLAST 
alignment tools, suggesting it would not affect other proteins. In 2012, there are over 100 
matches for homology with the control siRNA target sequence. The BLAST algorithm 
now shows 3 protein homologies with an E-value of 4.4 and 25 protein homologies with 
an E-value of 16 for the control siRNA target sequence within the rhesus macaque 
genome. Two of the top five matches of the query BLAST were known genes: G-
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coupled purinergic receptor 12 (P2RY12) and metallopeptidase 20 (MMP20) proteins. 
Using Ensembl genome browser and the Sequencher program the control siRNA SC47 
showed homology within ex on regions of these genes suggesting potential protein 
knockdown. Purinergic receptors have been shown to decrease paracellular permeability 
in human cervical cells by increasing tight junctional resistance (Gorodeski et al., 1998). 
While no work on P2RY12' s effect on Z0-1 expression distribution has been published it 
is possible that knockdown of P2RY12 could result in change of paracellular resistance 
affecting Z0-1 expression distribution. The matrix metallopeptidase family (MMP) of 
proteins are zinc-dependent endopeptidases that degrade extracellular matrix proteins. 
MMPs have been known to affect paracellular permeability in multiple ways. For 
example, MMP 13 has been shown to enhance permeability of endothelial cells by 
degrading the extracellular matrix (Lu et al. , 2009), and MMP9 can cleave occludin 
leading to increased endothelial permeability (Xu et al., 20 12). Furthermore, MMPs are 
known to aid in angiogenesis (Witmer et al., 2003). Again, while no work on MMP20' s 
effect on Z0-1 expression distribution has been published it is possible that knockdown 
of MMP20 would cause decreased Z0-1 perimeter expression. The control siRNA target 
sequence had a 12 nucleotide homology with both P2RY12 and MMP20 [Fig 4.1 & 4.2] . 
According to Jackson et al. only an 11 nucleotide homology region is necessary to cause 
knockdown (Jackson et al. , 2003). Thus, the decreased Z0-1 perimeter expression seen 
in control siRNA is possibly due to multiple protein knockdowns. Therefore, transient 
knockdowns of Tubedown were compared to RF /6A endothelial cells only transfected 
with GFP and not control siRNA transient transfections. 
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Figure 4. 1 BLAST Analysis of Control siRNA and MMP20 Homology. 
Using the BLAST algorithm I found thelvDv/P20 gene to have homology with our 
control siRNA (SC47) target construct. Using Ensembl I found the exon regions 
of:MMP20 and input the data into Sequencher. Sequencher predicts the control 
siRN A sequence to align with areas of ex on 8 and 9 in A1lv/P20. 
GENE I D: 710036 P2RY12 I purine r gi c r eceptor P2Y, G- protei n coupled , 12 
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Figure 4. 2 BLAST Analysis of Control siRNA and P2RY12 Homology. 
Using the BLAST algorithm I found the P2RY12 gene to have homology with 
our control siRNA (SC47) target construct. Using Ensembl I found the exon 
regions ofP2RY12 and input the data into Sequencher. Sequencher predicts the 
control siRN A sequence to align with an area of ex on 3 in P 2RY 12. 
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Immunofluorescence of Z0-1 in a stable Tubedown knockdown clone (ASTB) 
was used as a positive control, as per previous observations we continued to see 
decreased Z0-1 expression at the cell perimeter (Dr. H Paradis [Memorial University of 
Newfoundland], personal communication). However, transient knockdowns of 
Tubedown (Tbdn siRNA) when compared to GFP transfected RF/6A endothelial cells 
show no significant differences in Z0-1 perimeter expression [Fig. 3 .17]. It is possible 
that Tubedown affects Z0-1 perimeter distribution overtime, and the 72 hour culture of 
transient transfections showed no significant difference in Z0-1 distribution because of 
decreased culture times when compared to stable knockdowns of Tubedown. Maximal 
decreased Tubedown expression and tight junction formation is observed after 72 hours 
(Arenesen et al., 2009). However, a limitation to the transient transfection experiments 
was that Tubedown' s effect on Z0-1 perimeter distribution was not observed at 24 or 48 
hours. Therefore, the window in which the transient transfection had the highest effect 
on Tubedown expression and cell-cell contacts were formed may not have been at the 
time in which the cells were harvested. Furthermore, transient transfection GFP 
expression and Z0-1 perimeter expression were completed separately. Thus, quantitation 
of Z0-1 perimeter expression and Tubedown expression were not completed 
simultaneously, and therefore cell counting of Z0-1 perimeter quantitation may not have 
been completed on cells that were efficiently knockdown for Tubedown. It must be 
noted that ASTB #20 may be causing multiple protein knockdowns and therefore another 
protein is causing the relocation of Z0-1 in the stable knockdown clones of Tubedown. 
Experiments on Tubedown's effect on Z0-1 perimeter expression were exhausted with 
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materials readily available in the laboratory although no clear conclusion can yet be 
drawn on whether or not Tubedown exerts an effect on Z0-1 perimeter expression. 
Additional control siRNA's would need to be designed, and use of multiple knockdown 
clones of Tubedown would need to be used to conclude if Tubedown does or does not 
have an effect on Z0-1 distribution within the cell. Also, when completing Z0-1 
perimeter quantitation from transient transfections cells should have also been stained for 
Tubedown expression to determine if cells are efficiently knockdown for Tubedown. 
Furthermore, re-expression of Tubedown in stable knockdown clones should be 
completed to observe if Z0-1 perimeter expression is increased with increased Tubedown 
. 
expression. 
The results presented here lead me refute the hypothesis that Tubedown is 
regulating paracellular permeability through an interaction with AF -6 or Z0-1, or that 
Tubedown is regulating the transcellular permeability through an interaction with 
Dynamin-2 or c-Src. Furthermore, Tubedown's effect on Z0-1 perimeter expression is 
inconclusive. Tubedown in conjunction with Ard1 could possibly be inducing 
acetylation of Cortactin thereby decreasing its tyrosine phosphorylation aiding in the 
down regulation of the permeability within the retinal-choroidal endothelium. Tyrosine 
phosphorylation of Cortactin causes an increase in transcellular permeability (Cao et al, 
2010; Lambotin et al., 2005; Yang et al. , 2006). Tyrosine phosphorylation on Cortactin 
is antagonistic to its acetylation (Zhang et al., 2009). C-Src is known to bind and 
tyrosine phosphorylate Cortactin (Okamura & Resh, 1995). C-Src and Tubedown could 
be causing a shift in post translation modification balance of Cortactin by inducing 
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tyrosine phosphorylation and acetylation of Cortactin to regulate transcellular 
permeability, respectively. Evidence shows that c-Src tyrosine phosphorylates Cortactin 
to increase transcellular permeability (Cao et al, 2010; Lambotin et al. , 2005; Yang et al. , 
2006), and I speculate Tubedown is acetylating Cortactin thereby attenuating tyrosine 
phosphorylation and decreasing transcellular permeability [Fig. 4.3]. 
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Figure 4. 3 Hypothesized Mechanism for Tubedown's Regulation of 
Transcytosis. Tubed own is known to decrease transcellular permeability and 
specifically interacts with non-phosphorylated Cortactin (Paradis et al. , 2008). 
Cortactin tyrosine phosphorylation increases transcellular permeability, and its 
acetylation is antagonistic to its tyrosine phosphorlyation (Cao et al.,202 ~ Meiler et 
al. , 2012). Tubedown 1nay be inducing acetylation ofCortactin, thereby decreasing 
its tyrosine phosphorylation and attenutating transcytosis. 
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Tyrosine phosphorylation has been shown to increase both transcellular and 
paracellular permeability (Staddon et al., 1995; Andriopoulou et al. , 1999; Huber et al. , 
2001 ). Acetylation has been shown to affect the tyrosine phosphorylation status of 
proteins (Meiler et al. , 20 12). I speculate that Tubedown influences acetylation of other 
regulators of the permeability pathways attenuating tyrosine phosphorylation to decrease 
permeability. However, this model remains to be explored. While AF-6, Z0-1 , and 
Dynamin are not co-immunoprecipitating with Tubedown it is possible that Tubedown is 
acetylating these proteins through its interaction with Ardl. Z0-1 , Dynamin-2, VE-
cadherin, and Occludin are all examples of proteins that can be tyrosine phosphorylated 
resulting in increased permeability (Rao et al. , 2002; Cao et al. , 201 0). While Tubedown 
may not directly bind these proteins, it may be inducing their acetylation through its 
interaction with Ard1 and thereby decreasing their tyrosine phosphorylation. No work 
has yet been published on whether Z0-1 , Dynamin-1 , VE-cadherin, or Occludin can be 
acetylated. Further work to prove Tubedown-Ard1 can induce acetylation of these 
proteins could be assayed to test the hypothesis that Tubedown is inducing acetylation of 
permeability regulators while attenuating tyrosine phosphorylation. In addition, 
assessment of the tyrosine phosphorylation of permeability regulators in Tubedown 
knockdowns compared to parental cells could be completed to determine if Tubedown is 
attenuating their phosphorylation state. 
Tubedown' s mechanism of action in the regulation of permeability pathways 
within retinal-choroidal endothelial cells still requires further study. In this study, I have 
been able to exclude possible interactions of Tubedown with Dynamin, AF -6, Y 421-
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Phospho-Cortactin, c-Src, and Z0-1 within endothelial cell lines. I have provided 
evidence that Tubedown may regulate transcellular permeability by attenuating Cortactin 
phosphorylation within endothelial cells. In addition, Tubedown' s affect on Z0-1 
perimeter expression still remains inconclusive. 
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5.0SUMMARY 
The cumulative results of the protein interaction investigation suggest the role 
Tubedown has in regulating permeability pathways within retinal-choroidal endothelial 
cells does not likely involve interactions between Tubedown and Dynamin, AF -6, c-Src, 
or Z0-1. The specific interaction of Tubedown with non-phosphorylated Cortactin but 
not Y421-Phospho-Cortactin suggests that Tubedown may attenuate phosphorylation of 
Cortactin and subsequently decrease transcytosis. 
Stable knockdowns of Tubedown continued to show decreased expression of the 
paracellular permeability regulator Z0-1 at the cell perimeter. Transiently transfected 
Tubedown knockdowns suggest no significant difference in Z0-1 perimeter expression. 
However, the interpretations of knockdowns experiments are in question because of lack 
of specificity with controls. Therefore, no conclusion can be drawn on Tubedown' s 
effect on Z0-1 perimeter expression. 
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